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1 INTRODUCTION 
 
 
Biopharmaceuticals are medical drugs – proteins, antibodies and nucleic acids that 
are produced using biotechnology and are used for therapeutic or in vivo diagnostic 
purposes. The approval for human use requires several years of clinical trials.  
 
The first biopharmaceutical agent was insulin that was approved for human use in 
1982. Today, over 160 biopharmaceutical agents are approved in the USA and/or 
EU and most biopharmaceuticals are cancer-related. Besides diabetes and cancer, 
the biopharmaceuticals have advanced the treatment of rheumatoid arthritis and 
different blood disorders (Walsh, 2006). 
 
The markets of biopharmaceuticals have increased significantly over last years. 
Reasons for the rapidly increasing market value are naturally the increased number 
of products on the markets but also the fact that many of the therapeutic products 
are used in chronic diseases and in large quantities. As the new, efficient 
biopharmaceuticals are wanted to be available for more patients, increase in the 
manufacturing capacity is required.  
 
The development and manufacturing of these biopharmaceuticals is expensive and 
as a result the patient’s treatment costs may range from 10 000 € to even 100 000 € 
per year. The high costs of the biopharmaceuticals are partly explained by the long 
and expensive development time. The clinical trials take several years and still the 
drugs’ failure rate is 80 %. Manufacturing costs are also high, as clean room 
facilities and expensive methods are required. The biopharmaceuticals may also 
require administration by healthcare professionals, which obviously increases the 
costs. As the number of biopharmaceuticals is increasing, also the health care 
budgets will grow and the authorities may set maximum prices to the product. 
  
Because of the pressure to decrease the expenses, the focus is today in decreasing 
the manufacturing costs of the biopharmaceuticals. The manufacturing costs 
depend on the production host qualities, especially on expression levels and on the 
manufacturing process. The expression levels have already improved significantly, 
and now the processes must be evaluated more thoroughly. In biopharmaceutical 
  8 
field, the decisions of the production method and process steps have to be made 
earlier than in the normal process development, as after clinical trials none or only 
few modifications can be made. Therefore, the techno-economical evaluations in 
early process development phase are necessary in finding the optimal production 
method. 
 
In this thesis, different methods for producing therapeutic recombinant proteins and 
antibodies are reviewed and the manufacturing cost variables studied. Techno-
economical comparisons of different production hosts in recombinant protein 
production and different production methods in monoclonal antibody production are 
presented.  
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LITERATURE PART 
 
2 Production of biopharmaceuticals for therapeutic and 
diagnostic use  
 
 
Typical biopharmaceutical products for therapeutic and diagnostic use are proteins 
produced in microbial, mammalian or insect cell cultures using different bioreactor 
setups. The purification procedure depends on the characteristics of the product.  
 
 
2.1 Products  
 
The biopharmaceuticals include a variety of protein products such as recombinant 
proteins and monoclonal antibody- or nucleic acid-based products and vaccines as 
presented in Table 1. Here the focus is on recombinant proteins and monoclonal 
antibody based products. The first approved biopharmaceuticals in the 80’s and 
early 90’s were proteins with unaltered sequences or murine antibodies. Nowadays 
engineered products have captured the markets. The engineered products mean for 
example engineered proteins (e.g., insulin and interferon), humanized antibodies or 
antibody fragments (Walsh, 2005).  
 
Table 1. The different biopharmaceutical products (Walsh, 2006). 
Recombinant proteins 
 Blood factors (e.g. Factor VIII) 
 Thrombolytic agents (e.g. tissue plasminogen activator) 
 Hormones (e.g. insulin, growth hormones) 
 Growth factors (e.g. erythropoietin) 
 Interferons (e.g. interferon-α) 
 Interleukin-based products 
Monoclonal antibodies and antibody fragments 
Vaccines 
Nucleic-acid based products 
Therapeutic enzymes 
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On therapeutic field, the five major markets are the treatments or diagnostics for 
cancer, diabetes, growth disturbances, hemophilia and hepatitis. The biggest single 
product type based on sales was in 2005 erythropoietin (EPO). The combined sales 
of EPO products exceeded $10 billion (Walsh, 2006). In diagnostic field, the 
recombinant proteins and antibodies are usually used for detection of certain 
viruses or diseases.  
 
In 2006, approximately 162 biopharmaceutical products were approved in the USA 
and/or EU and recombinant proteins covered 70 % of these products (Figure 1). 
Monoclonal antibodies and antibody fragments together covered 18 % and vaccines 
12 %.  
 
 
Figure 1. The biopharmaceuticals approved in the US or EU until 2006, total 
number or approved products 162 (Walsh, 2006). 
 
In 2006 Walsh (2006) estimated that approximately 2 500 biopharmaceutical drugs 
were in the discovery phase, 900 in preclinical trials and 1 600 in clinical trials. 
Oncology was the most common indication target. Most products were either 
monoclonal antibodies or vaccines. Already in 2004 the Mab products were about 
25 % of all biopharmaceutical products in clinical development (Yang et al., 2004).  
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2.1.1 Biopharmaceutical markets  
 
In 2004 the combined market of biopharmaceuticals was estimated to $44 billion 
(Lawrence, 2005). The markets are projected to reach $70 billion by the end of the 
decade (Pavlou and Reichert, 2004; Pavlou and Belsey, 2005). Sommerfeld and 
Strube (2005) evaluate, that the global growth rate of the biopharmaceutical 
markets is approximately 10 %, whereas the average growth rate of antibody-based 
products exceeds 30 % and of other recombinant proteins over 15 %. The 
monoclonal antibody markets are estimated to continue to grow 20 % per year at 
least until 2010 (Johansson et al., 2007). As comparison, the traditional small-
molecule pharmaceutical markets face approximately 4 % annual increase.  
 
2.1.2 Recombinant proteins  
 
Walsh (2006) has grouped therapeutic recombinant proteins in five different 
categories: recombinant blood factors (used in indications of hemophilia), 
recombinant thrombolytics and anticoagulants, recombinant hormones (e.g. insulin 
and growth hormones), recombinant growth factors (e.g. erythropoietin), 
recombinant interferons and interleukins (used for example in indications of 
hepatitis).    
 
In therapeutic use the dose of a therapeutic protein e.g. erythropoietin or human 
growth hormone, is typically a few micrograms of protein (Aldington and Bonnerjea, 
2007). 
 
2.1.3 Antibodies  
 
Antibodies (or immunoglobulins (Ig)) are proteins that are used by the immune 
system. They are built of two heavy protein chains and two light protein chains. 
Antibodies are categorized in five different isotypes based on their heavy chain type. 
The most typical immunoglobulin class is IgG (see Figure 2).  
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Figure 2. IgG full-length antibody contains the heavy chain (VH, CH1, CH2 and 
CH3) and light chain (VL and CL) domains. The different chains are linked with 
disulfide bonds that are marked as dotted lines (Chadd and Chamow, 2001). 
 
The antigen binding sites, the variable regions are located at the tips of the Y-
shaped protein (VL / VH). The constant domain is located at the other end of the 
macromolecule.  
 
Recombinant antibodies are called monoclonal antibodies (Mab, mAb or moAb), 
because they are all identical and produced by a single clone of cells. The 
recombinant Mabs are grouped based on their protein origin (murine/human) 
(Werner, 2004):  
 
• Murine (mouse) antibodies are 100% murine protein and therefore their 
therapeutic applications are limited (side-effects, short serum half-life, inability to 
trigger desired immune effects) 
• Chimeric antibodies are genetically engineered and contain components of both 
murine and human proteins, approximately one third murine protein 
components. Can trigger allergic-like reactions.  
• Humanized antibodies are genetically engineered, almost all human protein. 
Only 5 – 10% of protein is murine origin. Can still trigger minor allergic-like 
reactions. 
• Fully human antibodies are from human cells or from genetically engineered 
murine. These have the lowest side-effect profile, and lower doses are needed 
as these are not eliminated as strange proteins in the body. 
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In 2006, 22 monoclonal antibody products were approved, and six of these were 
murine, five chimeric, nine humanized and two fully human (Walsh, 2006). The 
traditional method for production of Mabs is murine hybridoma cell cultivation. 
These products came in the market in the 80’s. Now the studies are more directed 
into chimeric and fully human Mabs (Pavlou and Belsey, 2005).  
 
Monoclonal antibodies are used as therapeutic agents (in gene therapy, in targeting 
objects, in neutralizing objects, in signaling or in cross-linking objects), in 
diagnostics, in immunoaffinity purification or as catalytic antibodies (also called 
abzymes or catmab’s) in enzyme engineering (Roque et al., 2004).  
 
As therapeutic agents, the monoclonal antibodies are focused on oncology and 
arthirits, inflammation and immune disorders (AIID), but they are also used in 
treating poisoning or viral infections and have become important treatment in 
chronic conditions (e.g. human malignancies).  
 
In diagnostic use, monoclonal antibodies are currently utilized in ELISA (Enzyme-
Linked ImmunoSorbent Assay) and RIA (Radioimmunoassay), and as imaging and 
immunosensor agents.  
 
Of the 22 whole monoclonal antibodies currently on the market, three are used in 
diagnostics or in indications of detection of cancer or carcinomas. Two of these 
Mab’s are murine and one fully human antibody (Walsh, 2006). Most of the 
diagnostic antibodies are not on the approved list, as they in vitro products do not 
need as thorough approval procedure.  
 
The need for large-scale monoclonal antibody processes is increased: they are 
used in chronic conditions and the doses needed are high, typical annual dose of a 
patient is 2 – 5 g (Sommerfeld and Strube, 2005). The high dosage is result of the 
relatively low potency (Birch and Racher, 2006; Chu and Robinson, 2001; Farid, 
2006; Reichert et al., 2005; Werner, 2004). The scale of antibody production 
depends on the field it is used: for research and toxicology studies the quantities 
needed are in µg or g range; for diagnostic applications of early-state clinical 
evaluations tens of grams or a few hundred grams; for late-stage clinical or for 
licensed products a few kilograms or hundreds of kilograms (Carson, 2005). 
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All approved therapeutic Mab’s are produced in mammalian cell cultures, but 
(Simmons et al., 2002) have published a study where they presented whole 
antibody production in E. coli (aglycosylated IgG1). Mab production has also been 
studied in yeasts and in fungi Aspergillus and studies are focusing on the correct 
glycosylation by these hosts (Birch and Racher, 2006).  
 
2.1.4 Antibody fragments 
 
An antibody fragment (Fab) contains the antigen binding region of the antibody, and 
therefore maintains the biological activity of the parent immunoglobulin (Figure 3). In 
a single chain variable fragment (scFv) the variable regions of the heavy and light 
chains are fused together (Figure 4). The scFv is half the size of the Fab fragment, 
but it still retains the original specificity. 
 
Until June 2006, six Fabs were approved in the US or within the EU (Walsh, 2006). 
Reichert et al. (2005) have listed the antibody based products in the pipeline and in 
2005, there were three Fabs and three scFv’s in phase III trials.  
 
 
Figure 3. An antibody fragment (Fab) contains the the VH, VL, CL and CH1 domains 
of an antibody (Chadd and Chamow, 2001). 
 
 
Figure 4. A scFv fragment contains only the antigen binding site (the VH and VL 
domains linked with a polypeptide linker) (Chadd and Chamow, 2001). 
 
  15 
Fabs, Fab’2 fragments and scFvs can be produced using microbial expression 
systems, although all approved antibody-based products are so far produced in 
mammalian cell cultivations. Yeasts and insect cell perform some degree of 
glycosylation (although it differs from the glycosylation performed by mammalian 
cells), but in bacterial cells, only aglycosylated antibody fragment products can be 
produced (Birch and Racher, 2006; Jain and Kumar, 2008; Reichert et al., 2005).  
 
Fabs have been produced in E. coli and P. pastoris and these products are now in 
preclinical and clinical trials (Chadd and Chamow, 2001; Farid, 2007; Reichert et al., 
2005). scFv’s have been produced in E. coli, P. pastoris and Drosophila insect cell 
lines (Andersen and Reilly, 2004; Holliger and Hudson, 2005; Johansson et al., 
2007).  
 
 
2.2 Host systems  
 
Most of the proteins and antibodies for therapeutic or diagnostic use are produced 
in either E. coli, Saccharomyces cerevisiae, or mammalian cell lines (Chinese 
hamster ovary (CHO), Baby hamster kidney (BHK) and hybridoma cells) (Chu and 
Robinson, 2001; Jana and Deb, 2005; Walsh, 2006). Between 2003 and 2006, 31 
new biopharmaceuticals (proteins and antibody-based products) were approved, 
and nine of these were produced in E. coli and 17 in mammalian cell cultures 
(Walsh, 2006). 
 
The host systems used in the production of approved therapeutic recombinant 
proteins (no monoclonal antibody- or nucleic acid based products) are shown in 
Figure 5.    
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Figure 5. Host organism in production of approved (until june 2006) therapeutic 
proteins (not Mab-based or nucleic-acid based) (Walsh, 2006). 
 
In case of monoclonal antibodies, the mammalian cell culture is the most used 
system. In 2006, all licensed antibodies were produced in mammalian cell systems. 
If the antibody based products are included into the scene presented in Figure 5, 
the mammalian cells are the most used system with share of 47 % (Walsh, 2006). 
Also most of the Mabs in clinical development were produced in mammalian cell 
systems (Birch and Racher, 2006).  
 
2.2.1 Selecting the right production host 
 
When choosing an expression host for production of a specific recombinant protein, 
one can essentially select from a multiplicity of different systems. The Escherichia 
coli bacterium is usually the starting point for any cloning and expression effort, 
because it has a variety of expression systems and is easy to cultivate. There is, 
however, no universal expression host system that would work optimally for all 
proteins. And even though the mammalian cell culture is more complex and 
expensive, it is often the only choice to produce large proteins that require extensive 
post-translational glycosylation. Therefore, when selecting the right production host, 
the glycosylation of the product must be the first criteria. Annual production 
requirements are often the second criteria. The higher the titer is, the lower the 
production volumes and therefore also the investment costs. The choice of the 
expression host also often determines the time-to-market, as the host development 
times vary significantly from host to host.  
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Each system has different advantages and disadvantages. In addition to the titer 
and the ability to perform post-translational modifications the practical issues to 
consider include means of induction and protease activity of the host. When aiming 
for industrial production, one has to consider a multitude of additional factors, such 
as the royalty burden of the host cell and vector, cost of raw materials, regulatory 
issues related to the host cell and vector (e.g. required containment level), harmful 
side-products (e.g. endotoxins, expression of tumor-associated proteins, baterial 
contaminants), reproducibility, up-scalability, and ease of host cell contamination.  
 
Cha et al. (2005) have compared the properties of different recombinant expression 
systems (E. coli, P. pastoris and insect cell lines) in human interleukin-2 (hIL-2) 
production. The different production systems were compared in terms of the 
productivity and product qualities. Beside their own studies, they also presented a 
comparison of the different expression systems based on literature data (Table 2.).  
 
Table 2. Comparison of recombinant expression systems (modified from Cha et 
al. (2005)). 
 E. coli Yeast Insect Mammalian 
Growth rate Very fast Fast Slow Very slow 
Expression yield (based 
on dry weight) 
High         
(1-5 %) 
High         
(>1 %) 
Very high 
(30 %) 
Very low  
(<1 %) 
Productivity Very high High High Low 
Media cost Very low Low High Very high 
Culture techniques Very easy Easy Difficult Very difficult 
Production cost Very low Low High Very high 
Protein folding Fair Good Very good Very good 
Simple glycosylation No Yes Yes Yes 
Complex glycosylation No No Yes Yes 
Secretion Poor Very good Very good Very good 
Availability of genetic 
systems 
Very good Good Fair Fair 
Pyrogen problem Possible No No No 
 
As can be surmised, the costs of E. coli culture are very low and mammalian cell 
culture very high. But as stated earlier, E. coli cannot perform even simple 
glycosylation.  
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2.2.2 Escherichia coli - bacteria 
 
Even though there’s many alternatives in the production of biopharmaceuticals and 
other recombinant proteins, E. coli is still used most widely, because it offers a rapid 
and economical production possibility (Andersen and Krummen, 2002; Schmidt, 
2004; Walsh, 2006). 
 
Sarramegna et al. (2003) stated that the main advantages of E. coli are the low 
production cost, homogeneity of the recombinant protein and short generation time. 
 
However, the tendency to form of inclusion bodies can be a problem in recombinant 
protein production, as the proteins should be refolded for adequate biological 
activity (Datar et al., 1993). E. coli also lacks the ability to perform post-translational 
modifications and there is no secretion mechanism for the efficient release of 
proteins into the culture medium (Jana and Deb, 2005).  
 
If no post-translational modifications are required, the E. coli is a good choice. For 
example many recombinant hormones (e.g. insulin) and interferons are produced 
commercially in E. coli (Walsh, 2006).  
 
2.2.3 Yeasts 
 
Engineered S. cerevisiae is used in the production of at least 10 approved 
biopharmaceuticals. These include most notably some insulin products and growth 
hormones. In addition to these, most of the vaccines now available are produced in 
S. cerevisiae. Most important of these are the recombinant hepatitis B vaccines 
(Walsh, 2006).  
 
No biopharmaceutical products have been produced in other yeast systems (data 
until 2006). Pichia pastoris would be an attractive host, because it can grow to high 
cell densities and is as easy to manipulate as E. coli but can also perform post-
translational protein modifications (Cha et al., 2005). However, the yeast performed 
post-translational modifications differ from those performed by mammalian cells 
(Chiba and Jigami, 2007).  
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When compared with mammalian cell systems, yeasts have faster growth rate, and 
generally also produce higher amounts of the protein product. In terms of 
production titer, P. pastoris is one of the most productive expression hosts, with 
recombinant protein titers even up to 14 g/liter (Clare et al., 1991). Additional 
advantage is the secretion of protein products into the growth medium, which 
usually makes the downstream processing easier (Cha et al., 2005).  
 
Unwanted glycosylation of the recombinant protein is a possible disadvantage of 
yeasts, but the degree of glycosylation depends on the strain as well as on the 
expression system used. Generally, the degree of glycosylation in P. pastoris is not 
as high as in S. cerevisiae (Schmidt, 2004; Schuster et al., 2000).  
 
2.2.4 Insect cells 
 
Among the new systems, insect cells are gaining ground rapidly (Ikonomou et al., 
2003). In 2007, the first vaccine (Cervarix® by GlaxoSmithKline, UK) produced in 
insect cells using the baculovirussustem was approved within the EU, in Australia 
and in Philippines. Cervarix® is a vaccine against certain types of the human 
papillomavirus that causes cervical cancer (Anon., 2008b). There is also another 
vaccine with the same implication, but it is produced in S. cerevisiae (Walsh, 2006). 
To date, many recombinant proteins made using insect cell lines have already been 
approved for use in veterinary medicine (Walsh, 2003).  
 
In comparison to mammalian cells, the ease of culture, high tolerance of osmolality 
and by-product concentrations, as well as higher expression levels are considered 
advantages of the insect cell systems (Ikonomou et al., 2003). Insect cells are also 
able to carry out the post-translational modifications some microbial systems can 
not, although the modifications still differ from those performed by mammalian cell 
cultivations (Cha et al., 2005). 
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2.2.5 Mammalian cells 
 
Almost all recombinant proteins that are produced in mammalian cell cultivations 
are produced with CHO and BHK (Walsh, 2003). Other mammalian cell lines used 
in biopharmaceutical productions are murine myeloma cell lines and hybridoma 
cells (Chu et al., 2005).  
 
Mammalian cell cultivations are the only way to produce large biomolecules that 
require specific glycosylation. The disadvantages of mammalian cells are the slow 
growth rate and very low expression yield. These factors make the mammalian cell 
cultivation very expensive and the manufacturing cost is further increased by 
expensive media and difficult culture techniques (Cha et al., 2005).  
 
All antibody-based products are also produced in mammalian cell cultivations. 
According to Farid (2006) most monoclonal antibodies are using cultivating 
mammalian cell systems in batch or fed-batch mode in stirred tank bioreactor. Mabs 
are purified generally using filtration and chromatography (Farid, 2006; Sommerfeld 
and Strube, 2005).  
 
In the last 15 years, the expression technologies and cultivation techniques (for 
example fed-batch and perfusion processes) have improved and resulted in 
significant improvements in antibody productivity of cell lines - even 100 fold (Birch 
and Racher, 2006). Now high cell line productivities (20 – 60 pg/cell/day) are 
relatively common and typical titers are in the range of 0.1 – 0.5 g/l. Also higher 
titers, even 1 – 5 g/l have been reported e.g. by Andersen and Krummen (2002), 
Birch and Racher (2006), Farid (2007) and Thiel (2004). With the improvements 
today the titers are expected to improve even to 10 – 15 g/l (Birch and Racher, 
2006; Farid, 2007; Werner, 2005). 
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2.3 Bioreactors and production strategies 
 
Bioproducts for therapeutic and diagnostic use can be produced in different types of 
bioreactors. The choice depends on e.g. the expression host and the production 
scale. Generally in large scale the stirred-tank bioreactor (STR) is the most desired 
option, as it is studied extensively and used in various systems for years. In 2001 
over 70% of all therapeutic proteins and antibodies on the market were produced in 
STR (Chu and Robinson, 2001; Kretzmer, 2002).  
 
The STR is probably the lowest cost alternative in large scale, where the costs are 
wanted to be decreased as low as possible. But in smaller scale, there are also 
other options for the bioreactor setup. Hollow fiber bioreactors are relatively 
common in small or medium scale commercial antibody processes. Most hybridoma 
cell lines are grown in air-lift or in hollow fibre bioreactors (HFB) (Chu and Robinson, 
2001; Kretzmer, 2002).  
 
Air-lift bioreactors (ALF) have been used mostly in production of monoclonal 
antibodies. In air-lifts, as also in STRs, both anchorage dependent and suspension 
cells can be grown. Air-lift reactors up to 5 m3 have been used and even 10 m3 air-
lift bioreactors have been reported for Mab production in hybridoma cultures by 
Lonza Biologics (Birch and Racher, 2006; Jain and Kumar, 2008) 
 
Perfusion technologies, such as hollow fibers and fixed-beds have several 
advantages: very high cell density, protection of the cells from the shear and high 
product concentrations. Disadvantages include limited mass transfer and difficulties 
in scale up, particularly of the hollow fiber system (Guardia and Hu, 2003). In fixed-
bed bioreactors the cells are immobilized on microcarriers and kept in a reactor and 
the media is circulated through the microcarrier beads. Fixed-bed bioreactors are 
high cell density culture bioreactor likewise the HFB, and have been used for 
perfusion cultures of mammalian cells. Fixed-bed bioreactors are used in 5 – 30 l 
scale (Jain and Kumar, 2008). 
 
The competition on the biopharma market is tough, and the time-to-market is often 
critical on the success of the product. As the cell line optimization is generally the 
most time demanding step, more emphasis is nowadays been placed on process 
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optimization and on the development of disposable bioreactors in order to shorten 
the time-to-market (Birch and Racher, 2006). The disposable bioreactors are a hot 
topic, but their size is limited so far to about 1 000 – 2 000 liter volume (Aldridge, 
2005; Anon., 2008e). 
The differences between stirred-tank and hollow fiber bioreactor in Mab production 
have been reviewed by Yang et al. (2004). Some of their data is shown in Table 3.  
 
Table 3. Comparison of stirred-tank and hollow fiber methods for Mab production 
(modified from Yang et al., 2004).  
 Stirred-tank Hollow fibre 
Oxygenation 
Mechanical agitation and gas 
sparging 
Diffusion and medium re-
circulation 
Cell density 
(1/ml) 
106 – 107 /ml >108 / ml 
0.2 – 0.25 µg/106 cells/h batch 
mode Specific 
productivities 0.29 µg/106 cells/h, cell 
retention, spin filter 
0.6 – 1.4 µg product /106 cells 
/h 
 
19.2 g/l/day, batch mode 
Volumetric 
productivity  110 mg/l/day, cell retention, 
spin filter 
500 – 3500 mg/l/day (based on 
the extracapillary volumes of the 
reactor) 
Cell damage by 
shear stress 
High, caused by agitation and 
gas sparging 
Low 
Culture stability 
High for continuous perfusion 
culture 
Detoration because of 
membrane fouling, cell clogging 
and accumulation of dead cells 
Scale-up 
potential 
High Low – limited by oxygen supply 
 
As mentioned before, the production scale and yield generally define the bioreactor 
type. In the presentation by Griffiths (2003), the different bioreactor types are 
categorized by volume and cell density requirements (Figure 6). 
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High volume, low density
(Homogenous)
20 000 l; 2 x 106/ml
(e.g., STR/ALF)
Medium volume, medium density
(Homogenous)
Perfusion <500 l; 1-2 x 107/ml
(e.g., spin filter)
Medium volume, high density
(Semihomogenous)
2-500 l; 1 x 107/ml
(e.g., microporous carriers)
Low volume, high density
(Heterogenous)
1-2 l; 2 x 108/ml
(e.g., hollow fibers)
Increasing cell density
  Volume
 
Figure 6. Bioreactor choice by scale (volume) and cell density requirements 
(Griffiths, 2003). 
 
2.3.1 Batch, fed-batch or perfusion? 
 
The bioreactors can be operated either in batch, fed-batch or in continuous 
perfusion mode. The different culture systems are presented in Figure 7. In batch 
system all nutrients are supplied in the beginning of the culture. The fed-batch is 
started at a low volume and the culture is later supplied with concentrated feed 
solution to maximum volume and no medium is removed. In chemostat the culture 
is constantly supplied with fresh medium and used medium and cells are removed 
simultaneously. In perfusion culture, fresh medium is supplied at the same rate than 
spent culture is withdrawn (biomass is returned or retained in the vessel). 
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Figure 7. Schematic bioreactor overview of the different culture systems: (A) 
Batch, (B) Fed-batch, (C) Chemostat and (D) Perfusion system (Dalm, 2007). 
 
In batch the cells grow until essential nutrients becomes limiting and the cells and 
product are harvested. The cell densities are generally about 5 x 106 cells/ml. In fed-
batch process the culture time may be longer (even 10 – 15 days) as nutrients are 
added during the cultivation. Cell densities of 107 cells/ml are achieved. In perfusion 
the nutrients are constantly added and also possibly inhibiting products are 
removed. Cell densities are significantly higher on perfusion processes (even 2 – 4 
x 107 cells/ml) and culture times can be 15 – 75 days (Dalm, 2007). 
 
In the production of therapeutic products (approved until 1999), batch and fed-batch 
processes were used more and perfusion only with few products, whereas for 
diagnostic products, the perfusion was preferred either in STR or in HFB system 
(Farid, 2006). This might be because the therapeutic products are produced in 
larger scale than the diagnostic products and as Bibila and Robinson (1995) state, 
the fed-batch is simpler to operate than the perfusion in large scale and can still 
produce over ten times higher titers than the batch process. The perfusion systems 
are considered more difficult because of the continuous operation, requirement of a 
cell-retention device and the long run time. In small to medium scales, the perfusion 
is more efficient way of production than the fed-batch. The high cell concentration in 
perfusion process results also in high product titers: productivities that are even 10 
times higher than in batch or fed-batch processes have been reported e.g. by Heine 
et al. (2000).  
 
In the continuous perfusion bioreactor, very high cell densities and consequently 
very high product throughput is achieved by retaining the cells in the reactor. The 
cells are either prevented to leave the vessel or separated by external recycling 
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device (Birch, 2003). Various cell retention techniques include filters, settlers, 
centrifuges or hydrocyclones (Castilho and Medronho, 2002; Voisard et al., 2003). 
The cell retention device may be positioned either inside or outside of the bioreactor 
vessel. At industrial scale the cell retention is usually done by centrifuges, settling 
devices or spin filters. The membranes and filters foul easily and therefore the 
rotated filters or baskets are widely used (Cartwright, 1994). The settlers were used 
up to 50 liter scale, the centrifuges up to 100 liter scale and the spin-filters up to 500 
liter scale (Voisard et al., 2003). In Figure 8, a typical spin-filter (or rotating filter) 
perfusion system is presented.  
 
 
Figure 8. Perfusion culture by a spin filter arrangement (Cartwright, 1994). 
 
According to Su (2000), the product quality is more consistent in perfusion system 
when compared to the batch and fed-batch processes. Small bioreactors and longer 
cultivation time also reduce the capital costs. The longer cultivation time means also 
fewer reactor turnovers, and therefore also less labor and energy costs (Castilho 
and Medronho, 2002). 
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2.3.2 Stirred-tank bioreactor 
 
With microbial cultivations, the stirred-tank bioreactor is almost always the choice. 
The optimization and scale-up of the STR is straightforward until certain size limit. 
Microbial cells are grown with different feeding strategies: batch, fed-batch or 
continuous. Conventional stirred-tank bioreactor is presented in Figure 9. 
 
 
Figure 9. Schematic drawing of a typical jacket-cooled stirred-tank bioreactor 
and the piping (Charles and Wilson, 2003). 
 
With the mammalian and insect cell cultures the STR technique is not quite as 
simple. As the cells are more shear sensitive than the microbes, the agitation and 
gas sparging can be a problem. Some cells are also so anchor-dependent that they 
cannot be adapted to grow in suspension. Microcarriers may sometimes enable also 
the anchor-dependent cell suspension culture, and when possible, the basic 
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suspension culture is used. With the most used cell lines these problems have been 
solved and they can be cultured in STR (Chu and Robinson, 2001).  
 
As has been stated earlier, generally the biopharmaceuticals are produced in 
suspension cell cultures (STR) using batch or perfusion mode. The cell culture 
densities in stirred tank bioreactors are generally limited by oxygenation, because 
the agitation and gas sparging has to be kept low. In these cultivations, the viable 
cell count is usually quite low, only 106 cells/ml and Mab volumetric productivity is in 
the range of 20 – 70 mg/l/day. With better feeding strategies and/or perfusion with 
cell retention the cell density of 107/ml can be achieved and therefore also 
significant increase in Mab productivity (up to 150 mg/l/day) (Yang et al., 2004).  
 
2.3.3 Hollow fiber bioreactor 
 
Hollow fiber bioreactors are perfusion bioreactors that can support extremely high 
cell densities (>109 cells/ml). The hollow fiber system gives a very large surface 
area for attaching cells and allows continuous removal of waste products and supply 
of nutrients (Griffiths, 2003). The hollow fiber bioreactor (Figure 10) consists of a 
series of capillary tubes, and the cells grow in the extracapillary space (ECS) and 
medium is circulated through the tubes i.e. in the intracapillary space (ICS). 
Ultrafiltration membrane is used frequently as a fiber material (Griffiths, 2003; 
Guardia and Hu, 2003). The product can be harvested from the extracapillary space 
through a sample port (Cartwright, 1994).  
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Figure 10. General arrangement of a hollow-fiber bioreactor, modified from 
Cartwright (1994). 
 
Hollow fiber bioreactors have been studied extensively e.g. by Gramer and Britton 
(2002) and Valdés et al. (2001) and the productivity can easily be more than 20-fold 
that of a suspension culture (Yang et al., 2004). Big advantage of the immobilized 
hollow fiber reactor is that the product fluid is cell free and thus easily purified. 
When using protein-free media, the Mab levels can be more than 40 % of the total 
protein in the product flow (Castillo, 2003). According to Davis (2007), in 
comparison to STR the HFB equipment is smaller (fits to normal ceiling height 
room) and utilities required include only CO2 and electricity whereas for the STR 
vast utility systems for O2, N2, compressed air, purified water, steam, drainage, CIP 
(clean in place) and SIP (sterilize in place) are required. As a result, for producing 
the same amount of product, the investment cost of the HFB is lower than that of 
the STR.  
 
Most hollow fiber bioreactors are in use in small scale. The scale-up has proved to 
be difficult: oxygen concentration in the medium exit end of the system becomes the 
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limiting factor at larger scale. In order to ensure the adequate oxygen supply, the 
medium to the system is typically directed through an oxygenator. Another method 
for improving aeration is to apply silicone tubing inside the system. This method is, 
however, rarely used, because it makes the bioreactor more difficult to 
manufacture. Also the flow direction in the system can be changed periodically, and 
thus improve the cells oxygen supply in the exit end of the system (Guardia and Hu, 
2003). The use of HFB is thus limited to small-to-medium scale. They also have 
relatively short operation life, because of the accumulation of dead cells and fouling 
of the membrane (Yang et al., 2004).  
 
However, when producing antibody products for research (laboratory scale, 10–100 
mg) or for diagnostic purposes (100 mg to several grams of antibody product), the 
HFB is a viable and economical alternative (Griffiths, 2003; Jain and Kumar, 2008; 
Valdes et al., 2001; Yazaki et al., 2001). They are especially good in hybridoma 
cultures that are generally difficult to grow in bioreactor suspension culture, as these 
cells are sensitive to shear and bubble damage (Yang et al., 2004).  
 
2.3.4 Disposable bioreactors 
 
“Disposables” mean single-used sterile bags, filters, of membranes, that are used in 
production or in product hold. Disposable bioreactors are sterile plastic bags that 
are inoculated, fed and aerated through plastic vents and that are generally mixed 
by keeping them on a swing. 
 
Disposable bioreactors are already use in medium scale production, Wave 
bioreactor (Wave Biotech, USA) can be used in over 500 l productions (Weber et 
al., 2002). Disposable stirred tank bioreactors (Hyclone and Baxter, USA) are for 
use for 250 l cultivations, maybe even 1000 l (Aldridge, 2005). XDR (Xcellerex, 
Marlborough, USA) single-use bioreactors are today available at 200 – 2000 l scale 
(Anon., 2008e). A figure of disposable Wave bioreactor is presented in Figure 11 
(Singh, 1999). 
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Figure 11. Disposable wave bioreactor (Singh, 1999). 
 
Disposables are a good alternative in production of small quantities of diagnostic 
products or therapeutic products for clinical studies. Many studies (e.g. Fox (2005) 
and Jain and Kumar (2008)) have evaluated the arguments for and against of the 
use of disposable bag bioreactors. They are an attractive choice for a bioreactor, as 
the investment costs are lower than in traditional plants and the costs are spread 
over a plant’s life (Farid et al., 2005b). 
 
The main advantage of the disposable bioreactors is that the cleaning and sterilizing 
issues are removed and that the investment costs are minimized (Farid et al., 
2005b). Other advantages are found in the reduced construction times and flexibility 
to modify the process configurations (Farid et al., 2005a). The downtime and 
turnaround times are shortened because no cleaning is required and there is a 
lower risk for cross-contamination as new bags are used for each run. Most of the 
biopharmaceutical facilities are multipurpose-plants, where the potential cross 
contaminations are a great concern, and the lower contamination risk is really an 
advantage (Carson, 2005). 
 
On the other hand, the main disadvantages are that the large-scale bags are 
unavailable and the operating costs can be increased significantly because of 
constant buying of new bags (Farid et al., 2005b). The other disadvantages include 
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the scale-up complications, reliance on suppliers and the increased expenses as 
the operating costs and waste costs are increased as also more solid waste is 
created in the process. Also more warehouse storage space is needed (Carson, 
2005; Farid et al., 2005a; Fox, 2005).  
 
Oxygen requirement is generally the limiting factor in larger scale, as the disposable 
bag reactors are usually operated through surface aeration. Singh (1999) studied, 
that the kLa values for disposable bag bioreactors (20 l and 200 l) were about 4 1/h, 
whereas they for similar size stirred tank bioreactors are usually around 50 1/h. The 
kLa values characterize the oxygen mass-transfer capability of a fermenter and with 
small kLa the oxygen delivery to the cells is limited. The oxygen mass-transfer can 
be improved for example using pure oxygen instead of air or increasing the air flow 
or impeller speed (Soderberg, 2002). 
 
As the scale is limited, also the use of disposable bioreactors is limited. But if the 
titers grow as expected (even to 10 – 15 g/l, e.g. by Birch and Racher (2006), Farid, 
(2007) and Werner (2005)), the 2 000 l scale now available could be enough for 
commercial production.  
 
 
2.4 Downstream processes 
 
The purification of a biopharmaceutical can be divided into three steps: capture or 
separation, purification and final polishing. The separation means mechanical 
separation, such as cell removal by microfiltration or centrifugation.  
 
In most cases chromatography is used in purification. The advantages of 
chromatography are the high selectivity and the gentle process. The most 
commonly used chromatographic techniques are affinity chromatography, ion 
exchange and hydrophobic interaction (HIC). Affinity chromatography is the most 
selective method, but unfortunately suitable affinity ligands are difficult to develop. 
Exceptions are the tagged proteins (i.e. GST or His(6) –tags) and monoclonal 
antibodies, that are commonly purified with glutathione sepharose, metal ion or 
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Protein A ligands, respectively (e.g. Low et al. (2007)). Another disadvantage is the 
high cost of the chromatographic resins.  
 
Regardless of the disadvantages, the Mabs and Fabs are almost always purified 
with affinity chromatography. Two different kinds of ligands are mainly used, either 
antigens that use the antigen binding abilities or less specific ligands that binds to 
the constant domain (Fc fragment). The most used are Fc binding natural 
immunoglobulin-binding ligands Protein G and Protein A. The disadvantages with 
these proteins are the high cost and the limited binding capabilities to Fabs. Other 
Fc region binding ligands are for example the Protein A mimics (synthetic affinity 
ligands) and peptide ligands (Huse et al., 2002; Low et al., 2007; Roque et al., 
2004). The specific antigen-ligands offer more selective means for purification, but 
the antigens may not be easily achieved. So called cross-reactivity can sometimes 
allow the use of non-specific antigen for purification (Huse et al., 2002). 
 
Even though chromatography as a method is easily up-scaled, the capacity of the 
downstream processing may become the bottleneck process when the production 
rates or titers increase. The limiting factors of the chromatography are the minimum 
residence time of the desired component and the maximum fluid velocity of the 
liquid phase (Kelley, 2007; Sommerfeld and Strube, 2005).  
 
The product must be free of viruses by FDA’s demand and therefore the viral 
contaminations must be removed (Sommerfeld and Strube, 2005).  
 
Sommerfeld and Strube (2005) have studied the downstream processes of several 
commercial monoclonal antibodies and have suggested a generic purification 
procedure (presented in Figure 12). After cell removal, the protein A 
chromatography is widely used as a capture step. Ion exchange chromatography is 
often used as a second chromatographic step as it removes possible DNA 
fragments and overflowed protein A. Additional chromatographic steps, such as 
HIC, are used if needed. With chromatographic methods, different membrane 
filtration techniques (micro, ultra and diafiltration) are used for cell/cell debris 
removal, concentration or buffer exchange. As a polishing step, diafiltration and 
sterile filtration is typically used 
 
  33 
 
Figure 12. A generic purification process of a monoclonal antibody purification 
from Sommerfeld and Strube (2005). 
 
Farid et al. (2007) states that the typical yield of antibody purification process is 60 –  
80 %, depending on the number of steps.  
 
 
2.5 Crystallization of proteins 
 
The crystallization of proteins is used in three different applications: in protein 
crystallography, in protein purification and in protein formulation for drug delivery. 
The most common application is the small scale crystallization of a protein for 
structural analysis. As a purification method, the low-cost crystallization could for 
example replace the expensive chromatographic step, but crystallization is almost 
never used in biopharmaceutical purification (Kelley, 2007; Low et al., 2007; 
Schmidt et al., 2005).  
 
The reason for the rare use of crystallization is the complexity of the crystallization 
of biological molecules. There is no universal method that would work to all proteins 
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or even groups of proteins. The method must always be searched through elaborate 
experimental work. Especially the monoclonal antibody crystallization is difficult 
because the molecules are large, flexible and highly glycosylated (Low et al., 2007). 
But the advantages of the crystallization would be low cost, high selectivity, high 
purity and unlimited scale-up potentials.  
 
In biopharmaceutical protein formulation, crystallization is used only for one product, 
insulin that is the only crystalline biopharmaceutical on the market so far. USA Food 
and Drug Administration (FDA) approved the first inhaled insulin product (Exubera, 
Pfizer, USA) in January 2006 (Anon., 2008c). Other crystalline products (e.g. α-
interferon) are currently in clinical trials. The challenge here beside in developing a 
crystallization method is to get a constant particle size in the crystalline product.  
  35 
3 Costs of the biopharmaceutical facility  
 
 
The competition on biopharmaceutical product market is increasing constantly, 
especially on high-market-value therapeutic drug section. On this competition, the 
time-to-market period is outstandingly significant. Shorter time-to market periods 
can be achieved by using either disposable based technology instead of 
conventional stainless steel stirred tank bioreactors or buying the manufacturing 
from a contract manufacturer. Time-to-market period is also affected by the 
expression host selection. 
 
But beside to shorter market times, the companies want also to reduce the 
manufacturing costs. Manufacturing costs now represent 20 – 25 % of annual sales 
of commercial monoclonal antibody products (Farid, 2007) but there is nevertheless 
pressure to reduce the manufacturing costs form thousands of dollars to hundreds 
of  dollars (Chadd and Chamow, 2001; Farid et al., 2005b). The prices (and 
resultant sales) will be reduced as the scales are increased and also the authorities 
may set maximum prices to the products (Sommerfeld and Strube, 2005).  
 
Factors that are most critical on biopharmaceutical (antibodies and recombinant 
proteins) product manufacturing costs are the fermentation titer and the overall 
yield. The fermentation titer depends mainly on the host cell expression system, the 
genetic stability of the host cell or cell line and the cell density. The overall yield on 
the other hand is a result of the downstream process steps – of the number of the 
steps and the step yields. Total productivity is affected also by the scalability of the 
process, process robustness and success rates of the large scale fermentations 
(Farid, 2007; Werner, 2004).  
 
Purification costs are significant in biopharmaceutical production. Purification costs 
are the highest in cases of inclusion body formation or in monoclonal antibody 
production. In therapeutic monoclonal antibody production (or antibody derivates), 
the downstream processing costs are 50 – 80 % of the total costs. Therefore, if the 
overall price of Mab and Fab products is wanted to be decreased, the efficient 
recovery of products must be the goal of the studies (Roque et al., 2004).  
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Usually in bulk chemical production or even in bulk biotechnology product (industrial 
enzymes) the process development continues until the plant construction and even 
during the production stage. But in biopharmaceutical product manufacturing the 
process is inevitably defined in early stages of the project. This is because the 
process itself defines the product quality as no reliable chemical analyses are 
available for these macromolecules (Sommerfeld and Strube, 2005). Thus, after the 
pilot phase and product manufacturing to the first clinical trials, no modifications to 
the process (to equipment, unit operations, number of steps and process 
parameters) can be done. Therefore, the different options for the process and their 
performance and economy must be regarded well in before hand.  
 
In this section, the studies regarding cost analysis are reviewed. All numbers are 
presented in Euros (€). The numbers that were presented in US dollars ($) in 
references are converted into Euros (€) with exchange rate 1€ = $1.5.  
 
 
3.1 Investment costs  
 
Investment costs (fixed capital investment, FCI) generally include the costs of 
purchased equipment, piping, instrumentation and utilities as well as the 
construction expenses for the buildings. In chemical engineering textbooks the fixed 
capital investment (FCI) is usually divided into direct and indirect costs as presented 
in Table 4 (Peters et al., 2003). The typical FCI distribution used in Finland is given 
in Table 5 (Hurme, 2008). The distributions used in the U.S and in Finland have 
some differences. In the Finnish distribution there is no division into direct and 
indirect costs. The indirect costs are not presented in such a detailed way. Also the 
content of purchased equipment installation is not equivalent to the FCI distribution 
used in the U.S. Start-up costs are included in the Finnish distribution   
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Table 4. The distribution of the fixed capital investment cost (Peters et al., 
2003). 
FCI = Direct costs + Indirect costs 
Direct costs 
1. Purchased equipment 
 
• All equipment listed on a complete flowsheet 
• Freight charges 
2. Purchased equipment installation 
 
• Installation of all equipment, structural supports and equipment insulation and 
painting 
3.  Instrumentation and control 
 • Purchase, installation and calibration of instrumentation  
4. Piping 
 • Pipes, hangers, valves and pipe insulation, installation 
5.  Electrical systems 
 
• All electrical equipment (switches, motors, wires etc.) installed 
• Electrical materials and labor 
6. Buildings 
 
• Process and auxiliary (offices, warehouses, laboratories) buildings 
• Building services (plumbing and HVAC etc. systems) 
7.  Yard improvements 
 • Site development (site clearing, grading, roads, fences etc.) 
8. Service facilities 
 
• Utilities (steam, water, power, compressed air, fuel, waster disposal) 
• Facilities (water treatment, cooling towers, electric substation, fire protection) 
• Non-process equipment (office furniture and equipment, safety and medical 
equipment etc.) 
• Distribution and packaging (raw material and product storage and handling, 
product packaging equipment, loading stations) 
9. Land 
 • Surveys and fees, property cost 
Indirect costs 
1.  Engineering and supervision 
 
• All engineering tasks (e.g., process, design, general, cost eng.) and 
engineering supervision and inspection 
2. Legal expenses 
 
• Preparation and submission of forms required 
• Contract negotiations 
3.  Construction expenses 
 
• Construction tools and equipment 
• Construction supervision, accounting, purchasing etc 
• Taxes, insurances, interest 
4.  Contractor’s fee 
5. Contingency 
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Table 5. The distribution of the fixed capital investment cost, Finnish system 
(Hurme, 2008). All categories include installation. 
FCI 
1. Purchased equipment (incl. freight charges and installation) 
2.  Instrumentation and control  
3. Piping  
4.  Electrical systems  
5. Steel structures  
6. Buildings (only process area) and yard improvements 
7.  Plumbing and HVAC 
8.  Insulation 
9. Painting 
10.  Land 
11.  Building site arrangements 
12. Engineering 
13. Start-up costs 
14. Contingency 
 
Quite often in prefeasibility study phase the total FCI is calculated from the 
purchased equipment expenses using the Lang method (Lang, 1948), see section 
3.1.1.  
 
In case of conventional biopharmaceutical product facilities, largest purchased 
equipment expenses originate from the bioreactors. The choice of the bioreactor 
type (stirred-tank reactor, air-lift bioreactor, hollow fiber bioreactor or disposable 
bioreactors) is affected by many factors that are related to the characteristics of the 
host microbe or cell line (most important is the anchorage-dependency of the cell 
line) and to the scale of the production (e.g., Chu and Robinson, 2001; Wang et al., 
2005). The production scale is further affected by the demand of the product and by 
the titer. The different bioreactors and the factors influencing the bioreactor 
selection are discussed in more details in section 2.3. 
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3.1.1 Lang method 
 
In the Lang method (Lang, 1948) the FCI of the manufacturing facility can be 
estimated with Lang’s factor from the cost of the purchased equipment of the plant. 
The accuracy of this method is approximately 40 – 50 % and the method is best 
suited for prefeasibility study phase. In this method (Equation 1), the total cost of 
delivered equipment (CE) is multiplied by Lang’s factor (L).  
 
CELFCI ⋅=  (1.) 
 
For greater accuracy, the Lang’s factor (L) can be calculated from separate factors 
(fi) for installation, piping, etc. as shown in Equation 2.  
 
i
j
i fL 1=∑=  (2.) 
  
For chemical engineering facilities, the Lang’s factor generally is in the range of 3 – 
5 depending on the process (Peters et al., 2003; Sinnott, 1999). For 
biopharmaceutical facilities values in the range of 3.3 – 8.1 for Lang’s factor have 
been suggested (Farid et al., 2005b; Farid, 2007; Novais et al., 2001). In their case 
study of Fab production in E. coli Novais et al. (2001) derived a Lang’s factor of 8.1 
for conventional STR based plant. They also presented correction factors for 
disposable bioreactors based plants (modified Lang method, see section 3.1.2). 
Datar et al. (1993) and Rouf et al. (2000) used a Lang’s factor of 4.6 for a 
mammalian and bacterial cultivation facility. 
 
One reason for higher Lang’s factors in GMP facilities compared to bulk chemical 
manufacturing facilities is that in GMP facilities the HPAC/HVAC (heating, 
plumbing/ventilation and air-conditioning) costs are higher because of the higher 
containment level.  
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3.1.2 Modified Lang method 
 
In the modified Lang method presented by Novais et al. (2001), the FCI of the 
disposable reactor based plant is calculated from the equipment cost of the 
conventional plant (CEconv) using a modified Lang’s factor (Ldisp) as presented in 
Equation 3. 
 
convdispdisp CELFCI ⋅=  (3.) 
 
The Lang’s factor for the conventional reactor based system was calculated 
(Equation 4) from capital investment factors (fi, where i = 1…10) representing 
various investment items (Table 6) and multiplied by contingency factor (c).  
 
iiconv fcL 101=∑=  (4.) 
 
For modified Lang’s factor (Ldisp) calculation the factors (fi) were corrected by 
translation coefficients (fi*) (Equation 5).  
 
*10
1 iiidisp ffcL =∑=  (5.) 
 
For the capital investment factors and translation coefficients see Table 6. The case 
presented by Novais et al. (2001) was a small scale (300 l) E. coli Fab-fragment 
facility, and in disposables based facility also the bioreactors were disposable. 
 
Also Sinclair and Monge (2005b) have presented similar comparison of Lang’s 
factors for conventional and disposable based 1000 l mammalian cell processes 
(Table 6), but in their case study, the inoculum, seed cell and production cultures 
are grown in conventional bioreactors in both processes. The disposables were 
used mainly in solution preparation and handling, in downstream processing and in 
product hold. 
 
However, although the translation coefficients and also the Lang’s factors are 
different, in both cases the Lang’s factor for disposable based process is 
approximately 40 % lower than the Lang’s factor for conventional process.  
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Table 6. The Lang method capital investment factors and translation coefficients 
presented by Novais et al. (2001) and Sinclair and Monge (2005b). 
 Convent.   
(fi) 
Disposable 
(fi
*) 
Convent.   
(fi) 
Disposable 
(fi
*) 
Reference Novais et al. (2001)* Sinclair and Monge (2005b)** 
Equipment 
(including utilities) 
1.00 0.20 1.00 0.55 
Pipe work and 
installation a 
0.90 0.33 0.51 0.55 
Process control 0.37 1.00 0.51 0.55 
Instrumentation 0.60 0.66   
Electrical power 0.24 1.00 0.20 0.27 
Building works 1.66 0.80 0.99 0.78 
Detail engineering b 0.77 0.50 1.39 0.61 
Construction and 
site management 
0.40 0.75 -- -- 
Commissioning 0.07 1.00 -- -- 
Validation 1.06 0.50 0.65 0.46 
     
Contingency factor 1.15 1.15 -- -- 
Lang's factor c 8.13 4.73 5.25 3.08 
* Scale 300 l, E. coli cultivation, disposables used in every step 
** Scale 1000 l, mammalian cell cultivation, disposables used only in solution 
preparations, downstream processing and product hold. 
a In Sinclair and Monge (2005b) model only pipe work 
b In Novais et al. (2001) model: detail engineering 
c In Sinclair and Monge (2005b) model the Lang’s factor is without contingency 
 
3.1.3 Investment cost estimates for biopharmaceutical product facilities 
 
Investment cost estimates for biopharmaceutical product facilities vary significantly 
depending on the production scale and concept type (conventional or disposables). 
The literature derived estimates are presented below and in Table 8. 
 
The investment cost estimates for a GMP multiproduct monoclonal antibody facility 
(up to 46 000 m2) are in the range of 4 700 € – 11 300 €/m2 (referred by Farid 
(2007)). When these numbers are related to the facility bioreactor capacity, the 
costs are suggested to be in the range of 1 200 €/l – 2 800 €/l for bioreactor 
capacities in the range of 20 m3 – 200 m3 so that the average investment cost for a 
bioreactor capacity of 20 m3 is 40 M€ and for a bioreactor capacity of 200 m3 400 
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M€. However Farid (2007) emphasizes that these cost estimates must be read with 
caution, as it is not always explained what the presented FCI’s above include (e.g. 
warehouses and utility systems). The data presented by Farid (2007) is shown in 
Table 7. 
 
Table 7. Capital investment costs for antibody facilities using mammalian cell 
culture (Farid, 2007). 
    Production bioreactor 
capacity 
 Facility Date  
facility 
completed 
Capital 
investment 
M€ 
number 
Size 
m3 
total 
m3 
1 
Genentech—Vacaville, CA, 
USA 
2000 167 8 12 96 
2 
Imclone—Branchburg 
BB36, NJ, USA 
2001 35 3 10 30 
3 
Biogen—LSM, RTP, NC, 
USA 
2001 117 6 15 90 
4 
Boehringer ingelheim 
expansion—Biberach, 
Germany 
2003 210 6 15 90 
5 
Lonza biologics expansion 
—Portsmouth, NH, USA 
2004 138 3 20 60 
6 
Amgen—BioNext, West 
Greenwich, RI, USA 
2005 333 9 20 180 
7 
Genentech NIMO** 
—Oceanside, CA, USA 
2005 253 6 15 90 
8 
Imclone—Branchburg 
BB50, NJ, USA 
2005 173 9 11 99 
9 
Biogen Idec—Hillerød, 
Denmark 
2007* 233 6 15 90 
10 
Lonza biologics 
—Tuas, Singapore 
2009* 167 4 20 80 
11 
Genentech expansion 
—Vacaville, CA, USA 
2009* 400 8 25 200 
* Expected completion date 
** Originally built by Biogen Idec and sold to Genentech in 2005 
 
The dependence of the FCI of the bioreactor capacity is studied by plotting the total 
production bioreactor capacity (m3) and the total capital investment cost (M€) 
presented in Table 7 on a log-log graph (Figure 13). From the plot, it can be seen 
that the data presented by Farid (2007) is quite linear (y = 1.9125x+10.304; R2 = 
0.85).  
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Figure 13. The dependence of the FCI (M€) on total bioreactor capacity (m3) by 
Farid (2007) and Werner (2004). The linear line represents the data presented 
by Farid (2007). 
 
According to Werner (2004) the total investment cost for a 6 x 15 m3 (total capacity 
90 m3) mammalian cell culture bioreactor facility is in the range of 300 M€ – 500 M€ 
(3 300 € – 5 600 €/l). Here the cost estimate depends on the type of the investment: 
greenfield (i.e. a new facility investment where also all utilities must be build) or an 
extension to an existing plant. Also the data of Werner is plotted on the graph above 
(Figure 13). As can be seen on Figure 13, the cost estimates presented by Werner 
(2004) are higher than the costs presented by Farid (2007).  
 
Novais et al. (2001) have presented investment costs for a conventional and a 
disposables based small scale (300 l) E. coli Fab facility. For conventional facility 
the FCI was 12.8 M€. For disposables based (using also disposable bioreactors) 
facility the FCI was calculated with a modified Lang method and the estimated FCI 
was 7.2 M€. Sinclair and Monge (2005b) have studied quite similar case in 1 000 l 
scale. In their study, the conventional process was similar to the one presented by 
Novais et al. (2001) but in their study conventional bioreactors were used also in the 
disposables based process. An earlier investment cost estimate for a recombinant 
  44 
protein producing facility has been presented by Datar et al. (1993) for E. coli and 
mammalian cell (CHO) cultures.  
 
The FCI estimates presented above are tabulated into Table 8.  
 
Table 8. The literature derived investment cost estimates on different 
biopharmaceutical product facilities. 
System FCI (M€) 
Bioreactor 
capacity 
(m3) 
FCI/ 
bioreactor 
capacity 
(M€/m3) 
Reference 
Multiproduct mammalian cell 
Mab facility, traditional 
40 – 400 20 – 200* 1.2 – 2.8 
(Farid, 
2007) 
Mammalian cell culture, 
traditional 
300 – 500 90** 3.3 – 5.6 
(Werner, 
2004) 
E. coli, Fab facility, traditional 
STR 
12.8 0.3 43.0 
(Novais et 
al., 2001) 
E. coli, Fab facility, 
disposable-based (also 
bioreactors) 
7.2 0.3 24.0 
(Novais et 
al., 2001) 
Mammalian cell Mab 
multiproduct facility, 
traditional 
38.5 1 38.5 
(Sinclair and 
Monge, 
2005b) 
Mammalian cell Mab 
multiproduct facility, uses 
disposables in buffer and 
solution handling 
22.6 1 22.6 
(Sinclair and 
Monge, 
2005b) 
CHO, rtPA facility, traditional 40.9 14*** 2.9 
(Datar et 
al., 1993) 
E. coli, rtPA facility, 
traditional 
259 17.3 15.0  
(Datar et 
al., 1993) 
* varied number and sizes  
** 6 x 15 m3 bioreactors 
*** In growth fermentation 4 x 7 m3, in production fermentation 2 x 7 m3 bioreactors 
 
 
3.2 Operating and manufacturing costs  
 
The costs of a (bio)chemical facility are divided into investment costs and operating 
costs. Operating costs include all the costs (materials, utilities, salaries, rent, 
laboratories, administrative etc.) that are originated from the manufacturing process. 
Direct or variable operating costs are directly related to the manufactured amount 
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(e.g. raw material expenses). The indirect operating costs or fixed overhead costs 
are independent of the manufactured amount (e.g. rent). The direct operating costs 
can be derived from the process flow diagram. The indirect costs are then derived 
as percentage either from the direct costs or from the FCI.  
 
Manufacturing cost includes the operating costs and the depreciation of the 
investment.  
 
3.2.1 Operating and manufacturing costs in U.S. literature 
 
The terms operating, manufacturing or production costs are often used as 
synonyms in the U.S. literature (e.g. Peters et al., 2003). In some sources the 
manufacturing cost is called the cost of goods. Manufacturing cost takes into 
account the depreciation of the investment and in some cases also the financing 
costs (interest).  
 
In Peters et al. (2003) the manufacturing cost is presented as in Equation 6. The 
general expenses are presented as in Equation 7 and the total product cost is the 
sum of manufacturing cost and general expenses (Equation 8). 
 
Manufacturing cost = variable production cost + fixed charges 
+ plant overhead cost 
(6.) 
 
General expenses = administrative expenses + distribution and 
marketing expenses + R&D 
(7.) 
 
Total product cost = manufacturing cost + general expenses (8.) 
 
The operating cost breakdown presented in Table 9 is generally regarded as correct 
(Humphreys, 1991). Some authors however disagree whether distribution costs are 
indirect or general expenses. 
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Table 9. Components of the total product cost (Humphrey, 1991). 
TOTAL PRODUCT COST: 
1. OPERATING COSTS OR MANUFACTURING COST: 
A. Direct production cost 
 1. Materials (raw materials, processing materials, utilities, etc.) 
 2. Labor (direct operating labor, operating supervision, etc.) 
B. Indirect production costs 
 1. Plant overhead (administration, laboratory, etc.) 
 2. Depreciation 
C. Contingencies 
D. Distribution costs 
2. GENERAL EXPENSES 
A. Marketing or sales costs 
B. Administrative expenses 
 
3.2.2 Operating and manufacturing costs in Finnish practice 
 
In the typical Finnish system the components of operating costs are calculated as 
presented in Table 10. The total operating cost is the sum of the variable and fixed 
costs.  
 
Table 10. The operating cost estimation in Finnish system (Hurme, 2008). 
OPERATING COST: 
1. VARIABLE OPERATING COST 
 Raw materials 
 Utilities 
Electricity 
Fuel 
Steam 
Water (process and cooling) 
Other utilities  
 Catalysts, solvents and operating supplies 
 Maintenance and repairs 
 Wastes 
2. FIXED OPERATING COST 
 Salaries 
 Insurance 
 Rent 
 Administrative expenses 
 Marketing 
 Research and Development 
 Quality control 
 Safety and protection 
 Medical expenses 
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The main differences to the U.S. system is that the Finnish system does not include 
the depreciation or financing expenses into fixed operating costs, but calculates 
them separately in the manufacturing cost calculation (Equation 9). 
 
The manufacturing cost in Finnish system is calculated from the operating cost 
(Table 10) and from the depreciation of the FCI as in Equation 9. 
 
Manufacturing cost = operating cost + FCI depreciation (9.) 
 
3.2.3 Operating cost models for biopharmaceutical facilities 
 
Several examples for fixed cost, plant overhead and general expense estimations 
for chemical facilities and traditional fermentations are found from the literature (e.g. 
Peters et al. (2003) and Sinnott (1999)). For GMP facilities fewer examples are 
found. In GMP biopharmaceutical facility for example the costs of HVAC, quality 
control and analysis (QCQA) as well as the regulatory costs are higher as 
compared to bulk chemical manufactory facilities (e.g. Farid et al. (2000)).  
 
Farid et al. (2007) have presented a model for biopharmaceutical facility simulation 
and in their model the cost of goods are calculated as presented in Table 11. In the 
model also the FCI depreciation is included.  
 
Table 11. Cost of good model presented by Farid et al. (2007) 
Direct operating costs Indirect costs 
raw materials  from flow sheet maintenance  10 % of FCI 
miscellaneous 
materials (e.g. 
safety clothing) 
50 % of the raw 
materials 
local taxes  2 % of FCI 
utilities  from flow sheet insurances  1 % of FCI 
labor  from personnel depreciation  FCI /  
depreciation period 
supervisors  20 % of the labor 
costs 
general utilities  300 $/m2 * facility 
size 
QCQA  100 % of the labor   
management  100 % of the labor   
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Generally, the costs of goods at commercial scale is in order of magnitude of 700 € 
per gram of concentrated biopharmaceutical therapeutic product (Farid, 2007), but 
there’s increasing pressure to reduce the costs 10-fold or even 100-fold (Chadd and 
Chamow, 2001).  
 
 
3.3 Manufacturing cost variables 
 
The investment and operating costs depend on various production parameters. The 
most important are the host, titer, scale, yield, feeding strategy and bioreactor type. 
The parameters are correlated, for example the titer depends on the host. The titer 
has a major influence on bioreactor scale and therefore on investment and 
operating costs. The production scale and the also the host’s characteristics 
influence the bioreactor type.  
 
The investment and operating costs are quite easily calculated for different titer and 
yield scenarios for one host, but the comparison of different alternatives is more 
laborious if different hosts are used in the production as almost all parameters are 
changed. The bioreactor type may be different for example for microbial and 
mammalian cell cultures and also the purification procedure is probably different. 
Operating costs are unequal for different hosts as the host defines the medium 
complexity and cost and also different purification steps result in different costs. 
 
The main possibility to decrease the costs of the upstream process lies in the 
increased titer. The titer can be increased first by increasing the specific production 
rate (g/g/h) by changing the conditions or by genetically engineering the host. 
Secondly the titer increases with higher cell concentration. Sommerfeld and Strube 
(2005) give theoretical maximum product concentrations that are 10 g/l for 
mammalian cell cultivations and 40 g/l for E. coli. The downstream costs can be 
decreased by reducing the number of purification steps and/or increasing the step 
yields. 
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3.3.1 The effect of titer, feeding strategy and scale on the costs 
 
The titer has an enormous effect on investment and operating costs. Therefore 
increasing the titer has been the topic of many research groups and as a result the 
titers are now much higher than before (Birch and Racher, 2006; Farid, 2007; 
Werner, 2005). If simultaneously the yield is increased, the effect is even more 
positive. Werner (2004) calculated, that on 10 m3 bioreactor scale and on 250 kg/a 
production rate with 10-fold increase in titer and simultaneously a 30 % increase in 
the overall yield, the number of bioreactors could be decreased from 31 to 2 and the 
resulting investment costs are decreased from 1067 M€ to 67 M€. At the same time 
the annual operating cost were decreased from 250 M€ to 43 M€.  
 
The titer may be increased for example with optimized feeding strategy. Typically 
the processes now are fed-batch or perfusion operations. Carson (2005) states, that 
also the product quality is more constant when moving away from batch processes 
towards fed-batch and perfusion operations. 
 
The effect of feeding strategy (fed-batch and perfusion) to the mammalian cell 
process economics has been evaluated e.g. by Lim et al. (2006), Farid (2007) and 
Werner (2004). In perfusion processes the productivities are higher and the 
investment costs lower as compared to the same numbers of fed-batch processes. 
The higher productivities are direct result of higher cell densities, as on perfusion 
process the cell densities are generally 10 or even 100 times higher than in fed-
batch process (Bibila and Robinson, 1995) and therefore the bioreactor sizes are 
smaller. However, the operating costs were be same for both systems in Lim and 
co-worker’s study (2006), as in perfusion culture the medium consumption was 
larger (2.6-fold) than in fed-batch operation. They also state, that the operational 
risks are higher (the probability of contamination of fouling can be even 10 %) on 
perfusion culture.  
 
Generally, in larger scale (if larger bioreactors are used), the investment cost per 
capacity liter is lower. Therefore, the operating and especially the material costs rise 
to more dominating position. As Rouf et al. (2000) demonstrate in Figure 14, the 
manufacturing cost distribution is different on different scales.  
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Figure 14. The manufacturing cost distribution depending on scale (Rouf et al., 
2000). 
 
From Figure 14 it can be seen, that on smaller scale, the labor costs are in more 
significant position than in larger scale. The larger the scale the more significant are 
the material costs. The depreciation of the FCI is around 10 % of the manufacturing 
cost, independently on the scale.  
 
Generally, the scale-up is done by implementing larger equipment, but it can be 
achieved also by multiplying the existing process. The scaling of a batch process by 
increasing the number of reactors instead of growing the size of a reactor has been 
studied by Rouf et al. (2000). They have compared the investment and operating 
costs of a single 6 m3 bioreactor (case A) and of six 1 m3 bioreactors (case B) for 
production of 11 kg rtPA (Table 12). The bioreactor cultivation and downstream 
processing times were same for both cases, as in single reactor case, larger 
downstream processing units were needed. In multireactor case, the modular 
approach allowed the downstream processing units to be scheduled better. As a 
result, in both cases, one set of downstream processing units was enough, but in 
single reactor case the equipment were larger. The total investment costs in the 
smaller scale were significantly (47 %) lower. The downstream processing costs 
were about 80 % of the total costs. The operating costs are more dependable of the 
mass of product and not so much of the bioreactor size. Therefore, although the 
operating costs of the multireactor case B were 24 % lower, they were not affected 
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as much by the bioreactor setup. In the operating costs of the multireactor case B, 
labor costs were twice the expenses of the single reactor case A. However, the 
increased need of SIP and CIP processes in the multireactor case were not 
included in the operating costs.  
 
Table 12. The cost analysis of the single 6 m3 bioreactor case compared to the 
six 1 m3 bioreactors case (Rouf et al., 2000). 
Cost factor Case A: 
6 m3 bioreactor 
Case B: 
6 x 1 m3 bioreactors 
Equipment cost 1.9 M€ 1 M€ 
Bioreactors of PEC* 14 % 37 % 
Chromatography columns of PEC* 52 % 33.3 % 
FCI (Lang’s factor 4.6) 8.7 M€ 4.6 M€ 
Operating cost 13.5 M€ 10.3 M€ 
*PEC = Purchased equipment costs 
 
Rouf et al. (2000) stated that besides the economical benefits from size reduction of 
the downstream processing equipment, the multiple bioreactors have also other 
advantages: flexibility of operation, minimized risks of contaminations and ease of 
start up and inoculum preparation.  
 
3.3.2 The effect of the equipment type on the costs 
 
Most of the large scale biopharmaceutical facilities use stainless stirred tank 
bioreactors. They are straightforwardly scaled and easy to sterilize and handle. The 
STR can be used, if the production host cells are adapted to grow in suspension. 
Disposable bioreactors offer an inexpensive alternative for the stainless steel stirred 
tank bioreactors, but the scale of the disposable bioreactors is limited. According to 
Farid (2007), for inoculum cultivation or clinical material preparation, the STR 
bioreactors are more and more been replaced by disposable bioreactors. Now the 
disposables are limited in 500 l (Wave bioreactor, Wave Biotech, NJ, USA (Anon., 
2008d)) or 200 – 2000 l (XDR, Xcellerex, Marlborough, MA, USA (Anon., 2008e)) 
scale.  
 
  52 
Besides replacing the actual production bioreactors, the disposables are being used 
in traditional facility for buffer preparation and in downstream processing (Farid et 
al., 2005b). Several comparative hypothetical studies of the costs of the 
conventional and disposable-based processes have been presented e.g. by Farid et 
al. (2005a), Farid et al. (2005b) and Novais et al. (2001) and these studies are 
discussed in the following.  
 
The investment cost and manufacturing cost analysis for conventional and 
disposables-based E. coli Fab-fragment facility (300 l) has been compared by 
Novais et al. (2001). In their study, in the disposables based facility all possible unit 
processes were performed by using disposables. The bioreactors were disposable 
bioprocessing containers with plunging-jet design for mixing and all membranes 
were single-used. The investment cost calculations of the conventional process 
were based on actual purchased equipment data and the investment costs of the 
disposable-based process were calculated by using the Modified Lang method (see 
section 3.1.2). Resulting investment cost (Table 13) of a disposable-based facility 
was significantly lower (7.2 M€) than the cost of a conventional STR facility (12.8 
M€). 
 
Table 13. Investment costs of conventional and disposable-based small scale E. 
coli Fab facility (Novais et al., 2001). 
 Conventional 
process 
Disposable-based 
process 
Purchased equipment cost of 
conventional process (CEconv) 
1.6 M€  
Langs’ factor 8.13  
Modified Lang’s factor  4.73 
FCI 12.8 M€ 7.2 M€ 
 
The manufacturing cost in the disposable-based facility (14.7 M€/year) was 
significantly higher than in the conventional facility (8.5 M€/year). This is mainly 
because the material expenses (Table 14) of the disposable-based facility were 16 
times higher than of the conventional facility.  
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Table 14. The material cost estimated for 300 l conventional and disposable-
based Fab processes (Novais et al., 2001).  
 Conventional 
process 
Disposable-based 
process 
Material cost unit k€/year % of 
total 
k€/year % of 
total 
Raw materials 24 33 % 92 8 % 
Membranes 39 53 % 777 64 % 
Matrices (IEX) 11 15 % 213 18 % 
Other disposable equipment 0 0 % 127 11 % 
Total material cost 73  1209  
 
In the material cost estimates presented on Table 14 the raw materials for 
disposable-based process were thought to be bought preprepared and sterile, and 
for the conventional process they were sterilized in-situ. The membranes and 
matrices were in conventional process used 20 times and only once in the 
disposable-based process. As a result, the material costs of the disposable-based 
process were 16.5 times the material costs of the conventional process.  
 
Other manufacturing cost items are presented in Table 15. The percentages of the 
conventional process manufacturing cost breakdown are modified from the 
breakdown presented by Datar et al. (1993). The item “other” here includes costs 
such as patents and royalties, waste and indirect manufacturing expenses. To 
estimate the cost of disposables-based process based on the conventional process 
cost data, Novais et al. (2001) have generated correction factors (y’) shown in Table 
15. The costs of the conventional process were multiplied by the correction factor to 
get the disposable-based process cost.   
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Table 15. The manufacturing cost breakdown of conventional and disposable-
based small scale (300 l) Fab facility by Novais et al. (2001). 
 Conventional 
process 
Disposable-based process 
 % of 
total 
M€/year Correct. 
fact. y’ 
M€/year % of 
total 
Labor costs 14 % 1.2 1 1.2 8 % 
Materials 6 % 0.5 16 8.2 55 % 
Utilities 14 % 1.2 0.5 0.6 4 % 
Depreciation 19 % 1.6 0.6 1.0 6 % 
Other 47 % 4.0 1 4.0 27 % 
Total manufacturing cost  8.5  15.0  
 
In the study by Novais et al. (2001), the investment costs of the disposable-based 
process are approximately 60 % of the FCI of conventional process. However, the 
total manufacturing cost of the disposable-based process is almost twice that of the 
conventional process. This is mainly because of the extremely high material costs 
that result from single used matrices and membranes. In practice they would 
probably not be used only once, as the cost effect is so large.   
 
The investment cost and manufacturing cost analysis for conventional and 
disposable-based mammalian cell Mab facility (1000 l) has been compared by 
Sinclair and Monge (2005b). The perfusion process time was 25.5 days and the 
product concentration 0.3 g/l and 2000 l of media containing the Mab would be 
recovered daily. The recovery and purification followed the standard Mab sequence: 
concentration, protein A chromatography, ultrafiltration, ion-exchange 
chromatography and viral inactivation (Sinclair and Monge, 2005a). The procedure 
is similar than the one described by Sommerfeld and Strube (2005). 
 
The production was performed either using conventional methods or the 
disposables-based process using the disposables in buffer and media preparation 
as well as in product hold (hold vessels). It must be noted, that the bioreactors in 
both facilities were conventional. The process equipment costs for conventional 
facility were 7.3 M€ and for disposables-based facility 4.1 M€ (Table 16). In both 
facilities, the equipment for previral purification was the most expensive single 
operation. The most investment cost savings in disposable-based facility equipment 
costs came from the process utilities when the CIP and SIP requirements were 
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lessened and from the solution handling as disposables were used. Some 
equipment, such as autoclaves and washing machines could be totally removed 
from the concept facility. 
 
The FCI (Table 16) was calculated from the process equipment costs with Lang’s 
factors for installation, building, engineering and validation (see section 3.1.2). As 
the equipment costs were lower in disposable-based facility, also the FCI was 
significantly lower. Total savings in FCI were 41 %.  
 
Table 16. The FCI of the conventional and disposable-based facility in Sinclair 
and Monge (2005b). 
 Conventional (M€) Disposable-based (M€) 
Process equipment, total 7.3 4.1 
Previral purification 1.3 1.4 
Process utilities 1.1 0.1 
Solution handling 1.1 0.1 
Installation 8.9 4.5 
Building 7.3 5.7 
Engineering 10.2 6.2 
Validation 4.8 2.2 
Total 38.5 22.6 
 
Sinclair and Monge (2005b) calculated also the manufacturing costs from labor, 
material, indirect material (from labor expenses), consumables (filter membranes, 
chromatography media, single-use systems), capital depreciation (15 % capital cost 
in eight years time) and waste management (waste water and plastics incineration). 
They estimated that the number of personnel could be reduced from 190 to 153 in 
the disposable-based facility, most of the reductions being from the quality control 
personnel. The expenses of the consumables was the only cost factor that was 
increased in the disposable-based facility compared to the conventional one. The 
manufacturing cost (€/g) in the disposable-based facility was 17 % lower than in the 
conventional facility. 
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Table 17. The manufacturing cost of the conventional and disposable-based 
facility (Sinclair and Monge, 2005b). 
 Conventional Disposable-based 
 (€/g) % of total (€/g) % of total 
Labor 129.1 37 % 99.3 35 % 
Direct materials 39.7 12 % 36.8 13 % 
Indirect materials 53.0 15 % 47.9 17 % 
Consumables 26.3 8 % 49.2 17 % 
Depreciation 96.2 28 % 54.0 19 % 
Waste management 0.2 0 % 0.1 0 % 
Total 345  287  
 
In the study by Sinclair and Monge (2005b), the investment costs of the disposable-
based process are approximately 60 % of the FCI of conventional process. This is 
in accordance with Novais et al. (2001), although in the process by Novais et al. 
(2001) also the bioreactors were disposables. In the disposable-based process 
(Sinclair and Monge, 2005b), the direct material expenses are almost equal and the 
indirect material costs are even lower than in the conventional facility. Most 
manufacturing cost savings come from labor and depreciation expenses.  
 
The investment cost and manufacturing cost analysis for conventional, hybrid and 
disposables-based mammalian cell Mab facility (200 l) has been compared by 
Farid et al. (2005a; 2005b). In their hypothetical case study they compared three 
different equipment setups for a mammalian cell culture pilot plant in a start-up 
biopharmaceutical company. The titers and yields were assumed to be equal in all 
setups: 
A. A conventional pilot plant based on stainless steel equipment 
B. A pilot plant utilizing only disposable equipment (disposable air-lift or bubble 
column) 
C. A pilot plant utilizing stainless steel equipment for cell culture and otherwise 
disposables.  
The process Farid et al. (2005b) considered contained inoculum, seed and product 
fermentations, clarification, concentration, and purifications with three-step 
chromatography and final filtration. The pilot plant was designed assuming a typical 
product titer of 0.4 g/L at the 200 l scale and assuming a 56 % purification yield 
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resulting 45 g of purified antibody as would be sufficient for phase I clinical trials. 
Pilot was thought to be used for the production of several different products. Media 
and buffers were assumed to arrive pre-made and pre-sterilized. In alternative B, no 
SIP and CIP procedures were needed. The campaign turnaround time in 
conventional option (A) was 4 days, otherwise only 1 day. In 48 weeks/year the 
facility can perform 6 campaigns using the option A, 8 using B and 7 using C.  
 
The fixed capital investment was calculated by multiplying the total equipment cost 
by Lang’s factor. Farid et al. (2005b) used Lang’s factors of 7 for the conventional 
stainless steel option (A), 4 for totally disposables based option (B) and 5 for hybrid 
option (C). In options B and C they used the Modified Lang method (see section 
3.1.2) that was first presented by Novais et al. (2001). The manufacturing cost in 
Farids et al. (2005b) calculations included the materials, utilities, labor, fixed 
overheads and depreciation of the equipment (10 years period). 
 
The manufacturing costs (per gram of product) in the first year of operation were 30 
% lower in option B and 19 % lower in a hybrid option C as compared to the 
conventional stainless steel option A (Figure 15). This is mostly because larger 
amount of product could be produced annually due to shorter campaign turnaround 
times and larger number of campaigns. Facility overheads and depreciation charges 
covered over 50 % of the manufacturing costs in all options. Naturally, due to lower 
investment costs, the depreciation costs in options B and C were significantly lower 
than in A. In options using the disposables, the labor and utilities costs were smaller 
than in conventional option because of lack of cleaning and sterilizing processes. 
On the other hand, in conventional option, the material costs were lowest, as the 
chromatography matrices were re-used.  
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Figure 15. The manufacturing cost (per g of product) breakdown of different 
process options relative to the conventional option A (Farid et al., 2005b). 
 
The breakdown of the direct operation costs (per gram of product) on basis of 
different process steps (Figure 16) shows how significant the CIP and SIP expenses 
are in the conventional option (A). In disposable-using options B and C the need for 
cleaning and sterilizing operations are eliminated and therefore these expenses are 
reduced. On the other hand, it can be seen, how significant the chromatography 
matrix (mostly protein A) expenses are, if they are handled as single-use materials. 
 
 
Figure 16. The manufacturing cost breakdown: different process steps (Farid et 
al., 2005b). 
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Farid et al. (2005b) came to the conclusion, that the fermentation titer had the 
biggest impact on FCI and manufacturing costs. However, in their study it was 
assumed, that the titer was equal in all process options, and it is not yet possible to 
achieve the same titer in disposables as in STR.  
 
Farid et al. (2005b) did not present exact FCI numbers, but from the Figure 15 it can 
be seen that the depreciation expenses are significantly lower in the process 
options using disposables. Also the total manufacturing cost in disposable-based 
processes is lower than in the conventional process, although the direct material 
costs are higher.  
 
As a conclusion it is obvious, that in processes using disposables, the investment 
costs are significantly lower than in conventional processes. Both Novais et al. 
(2001) and Sinclair and Monge (2005b) estimated 40 % savings in total capital 
investment costs. Most likely also the total manufacturing costs in disposable-using 
processes are lower, although in the study presented by Novais et al. (2001) the 
manufacturing cost was almost double because of the extremely high material 
costs. The high material costs were thought to be because of single use 
chromatography matrices, but also in the study by Farid et al. (2005b) the matrices 
were used only once in disposable-based processes. But in Farid et al. (2005b) 
study the costs of CIP and SIP processes (utilities and labor) were assumed to be 
reduced more in the disposable using facilities than in the Novais et al. (2001) 
study. In Novais et al. (2001) study, the labor expenses were though to be the same 
in both facilities, but Farid et al. (2005b) and Sinclair and Monge (2005b) agree, that 
the labor expenses are significantly lower in disposables using facilities.  
 
3.3.3 The effect of the host on the costs 
 
The choosing of the production host was discussed earlier in more detail in section 
2.2 Host systems. The selected host must fulfill two possibly contrary needs: it must 
be suited to produce the desired biopharmaceutical and it must be economical with 
high enough titer.  
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The host influences both the investment and operating costs dramatically, since 
almost the whole process is different if different hosts are used. This is the case in 
the study by Datar et al. (1993), where the production of a recombinant-tissue 
plasminogen activator (rtPA) in E. coli and in CHO cells was studied. In their case, 
the glycosylation was not essential for the biological activity of the product, so it 
could be produced also in E. coli. In both systems, the main purification was based 
on affinity and gel chromatography. The E. coli product however was produced in 
inclusion bodies and therefore needed to be refolded. Thus E. coli system included 
more unit operations (e.g. sulfonation, refolding tanks and more concentration 
steps). Consequently in CHO process there were five purification steps, as in E. coli 
system there were approximately sixteen purifications steps. The production 
parameters and investment costs of the study of Datar et al. (1993) are summarized 
in Table 18.  
 
Table 18. The production parameters and economic indicators of the rtPA 
production by Datar et al. (1993). 
 Mammalian (CHO) Bacterial (E. coli) 
Annual production rate 11 kg 11 kg 
Annual number of batches 50 50 
Fermentation mode Batch, 5 – 7 days Batch, 1 – 2 days 
Fermentation titer 33.5 mg/l 460 mg/l 
Number of purification steps 5 16 
Overall yield 47 % 2.8 % 
Batch volume 
14 m3 
(2 x 7 m3 bioreactors) 
17.3 m3 
(one bioreactor) 
Purchased equipment cost  7.4 M€ 47.3 M€ 
FCI (Lang’s factor 5.5) 40.9 M€ 259 M€ 
 
The purchased equipment expenses of the mammalian cell process were about 16 
% of those of the bacterial process. In mammalian system the bioreactors were the 
biggest equipment expense (54 % of equipment cost), but in bacterial system the 
most expensive equipment was the refolding tanks (75 % of equipment cost). The 
refolding was done in very low concentration (2.5 mg/l tPA) that resulted in ten 180 
m3 refolding tanks and also to 4 500 m2 ultrafiltration membrane area.  
 
The direct operating costs consisted of used materials, utilities, labor as well as the 
waste expenses and patent and royalty costs (Table 19). Fermentation and 
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recovery materials were 44 % of direct operating costs in CHO and 9 % in E. coli. 
On the contrary, the labor expenses were 9 % in CHO and 22 % in E. coli. This is in 
accordance with the general opinion that in mammalian cell processes the material 
expenses are high. However, generally the downstream processing expenses are 
higher than in the presented cost breakdown. In bacterial production, the material 
expenses are the only expenses that are lower than in the mammalian cell process.  
 
Table 19. Direct operating cost of the rtPA production by Datar et al. (1993). 
 Mammalian (CHO) Bacterial (E. coli) 
Direct operating cost M€ % M€ % 
Fermentation materials 15.6 33 % 0.8 1 % 
Recovery materials 5.2 11 % 6.0 8 % 
Utilities 8.0 17 % 15.1 20 % 
Patents and royalties 8.0 17 % 15.1 20 % 
Waste 4.7 10 % 12.0 16 % 
Labor 4.3 9 % 16.6 22 % 
Other 1.4 3 % 9.8 13 % 
Total  47  75  
 
Total manufacturing costs included the direct operating costs, indirect operating 
costs, the depreciation costs and the general expenses. The direct operating costs 
were 60 % of total in CHO and 47 % in E. coli. The general expenses were about 30 
% of the total manufacturing costs in both cases. Total manufacturing cost 
breakdown for both processes is presented in Table 20 (the numbers are not scaled 
from the 1992 prices).  
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Table 20. Manufacturing cost breakdown of the rtPA production by Datar et al. 
(1993). 
 Mammalian (CHO) Bacterial (E. coli) 
Manufacturing cost unit M€ % M€ % 
Direct operating cost (DOC) 47 60 % 75 47 % 
Fermentation materials, % of DOC 15.6 33 % 0.8 1 % 
Recovery materials, % of DOC 5.2 11 % 6.0 8 % 
Utilities, % of DOC 8.0 17 % 15.1 20 % 
Patents and royalties, % of DOC 8.0 17 % 15.1 20 % 
Waste, % of DOC 4.7 10 % 12.0 16 % 
Labor, % of DOC 4.3 9 % 16.6 22 % 
Other, % of DOC 1.4 3 % 9.8 13 % 
Indirect operating costs 3 4 % 15 9 % 
Depreciation 3 4 % 21 13 % 
General expenses 25 32 % 50 31 % 
Total manufacturing cost 78  162  
 
As it can be seen from the results of Datar et al. (1993), the host’s effect on the 
process and investment and manufacturing costs is critical. Here the E. coli process 
is economically infeasible because of the formation of inclusion bodies and following 
very low refolding concentration (2.5 mg/l) and yield (20 %) that results in huge 
investments and low overall yield (2.8 %). However, Datar et al. (1993) states, that if 
the renaturation yield is increased from 20 % to 90 % (overall yield 15.4 %), the E. 
coli process is more profitable than CHO process.  
 
3.3.4 The effect of the purification procedure to the costs 
 
The purification process has a significant impact on overall manufacturing costs. 
Roque et al. (2004) and Rouf et al. (2000) state, that even 50 – 80 % of the 
manufacturing costs comes from downstream processes in production of Mabs and 
Mab derivates. As mentioned before, downstream processing costs can be 
decreased by reducing the number of steps and/or increasing the step yields. The 
dependence of the overall yield on the number of steps and on the step yield 
(Figure 17) was originally presented by Fish and Lilly (1984). 
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Figure 17. The overall yield dependance on the number of steps and on the step 
yield (modified from Fish and Lilly (1984)). 
 
Sommerfeld and Strube (2005) calculated that if the annual fermentation titer is 94 
kg and the step yield increases from 90 % to 95 % (total yield increases from 50 % 
to 70 %), the downstream processing manufacturing costs are reduced 22 %. In 
their calculations the manufacturing cost included the depreciation of equipment (10 
years time period), raw materials, consumables such as membranes and resins, 
labor and waste treatment.  
 
The significance of the downstream process costs on the total operating and 
manufacturing costs depends not only on number of steps and step yield but also 
on the scale and titer of the production. Harrison (2003) suggested that with annual 
capacity of 6.2 kg and titer of 0.1 g/l, the ratio of upstream to downstream costs was 
46:54, but with annual capacity of 100 kg and titer of 0.5 g/l the same ratio was 
20:80. Same trend is presented also in the calculations of Sommerfeld and Strube 
(2005): With titer of 0.1 g/l the ratio of upstream to downstream manufacturing costs 
was 55:45, with titer 0.3 g/l 46:54 and with titer 1 g/l 30:70. This is explained by the 
fact that with higher titers the upstream processing equipment and volumes are 
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smaller and therefore also the material costs and the depreciation of the upstream 
processing investment costs. But the downstream processing, mainly protein A 
chromatography, volumes are independent on the concentration and are dependent 
on the mass of the product. Thus, although the same amount of product could be 
produced in smaller volumes, the size of the downstream processing equipment is 
not changed as much.  
 
Sommerfeld and Strube (2005) state that the affinity chromatography costs could be 
decreased either by increasing the resin binding capacity or by increasing the resin 
lifetime. Especially the resin lifetime has major effect on operating costs. The costs 
of membrane filtrations that are generally considered as inexpensive rise quite high 
according to Sommerfeld and Strube (2005). This is mostly because the filtrate flux 
are quite low resulting to long processing times, and the required membrane areas 
are high resulting also high amount of buffers used. The cost of filtration is 
approximately one third of that of chromatography.  
 
 
3.4 Conclusions of the costs of the biopharmaceutical facility 
 
The investment costs of biopharmaceutical facilities have recently been reviewed 
e.g. by Farid (2007) and manufacturing costs of recombinant protein production has 
been presented e.g. by Datar et al. (1993) and Rouf et al. (2000) and antibody 
production e.g. by Novais et al. (2001), Sinclair and Monge (2005b), Farid et al. 
(2005b) and Sommerfeld and Strube (2005).  
 
The techno-economical analysis of different setups is relatively easy, if only titer 
and/or yield are changed and the process is otherwise kept the same. But if two 
different hosts are compared for commercial production, the comparison is more 
laborious as the processes may be completely different.  
 
As the competition on biopharmaceutical markets tightens up and the time-to-
market must be reduced, the disposable products come more and more interesting 
as the validation times are shortened. Based on the techno-economical 
comparisons found in literature, the use of disposables is also economically viable 
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alternative. In disposable-based processes, the investment costs are significantly 
lower and the material costs are typically higher than in conventional processes. 
Still, the total manufacturing cost is lower in disposable-based process, as cost of 
utilities, labor and QCQA are reduced.  
 
The titers have increased significantly over years and now the process development 
focus is more on the downstream processes. The impact of the downstream 
processing costs on total manufacturing costs is high and most purification costs 
emerge from the chromatography steps (usually protein A). Still, no real options for 
chromatographic purification are available.  
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RESEARCH PART 
 
4 Manufacturing costs of recombinant protein production in 
microbial and insect cell host systems 
 
 
The manufacturing costs of recombinant protein production were analyzed by using 
HIV-1 Nef (negative factor) as a model protein. Nef protein was produced in three 
different host systems, E. coli, Drosophila S2 and P. pastoris and the manufacturing 
costs of strain/cell line development, production and purification were calculated 
based on the experimental work (Vermasvuori et al., 2009).  
 
HIV-1 Nef is an approximately 27 kDa myristoylated protein of the primate 
immunodeficiency viruses (HIV and SIV). The protein is expressed in large amounts 
early in the virus replication cycle and it is essential for the progression of AIDS. 
The high importance of Nef for the viral life cycle and pathogenesis is clear (Arold 
and Baur, 2001; Deacon et al., 1995; Geyer and Peterlin, 2001). Because of its 
criticality in pathogenesis and development of AIDS, Nef is an attractive target for 
drug research as the molecules that could block the interaction sites of Nef could for 
example be used as therapeutic agents (Geyer and Peterlin, 2001). Nef is also used 
in clinical trials for analysis of the immunogenic response of other HIV vaccine 
candidates (e.g. DNA-based vaccines). The Nef protein encoding sequence has 
been included in some DNA-based vaccines (Blazevic et al., 2006; Krohn et al., 
2005). 
 
Techno-economical analysis of the three different host systems was based on the 
production and purification data presented for E. coli and Drosophila S2 in 
Vermasvuori et al. (2009) and for P. pastoris in Sirén et al. (2006). Only few similar 
cost analyses of the production of recombinant proteins in different host systems 
has been published previously. Datar et al. (1993) had studied the costs of 
recombinant therapeutic protein (rtPA) in E. coli and in mammalian system in large 
scale (see section 3.3.3).  
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Here the product was supposed to be produced for research or diagnostic use and 
the production goal was set at 100 mg of purified Nef protein (base case). The 
protein was supposed to be produced campaign-wise in one batch using a 
bioreactor of sufficient volume. As the titers of the hosts varied, the production 
expenses were calculated also for equal titers and for 10 l bioreactor scale (equal 
titer case).  
 
 
4.1 Production and purification data of Nef protein production 
 
The Nef protein was produced in three different host systems, E. coli, Drosophila S2 
and P. pastoris. In E. coli the Nef was produced as GST-tagged protein and the 
GST-tag was in purification cleaved by enzymatic cleavage. In P. pastoris and in 
Drosophila S2 the protein was produced with a hexahistidine-tail (His(6)-Nef), and 
the tag was not removed from the purified product.  
 
E. coli was cultured in fed-batch mode in 3.5 l stirred-tank bioreactor, and the 
production time was about one day. Approximately 30 g/l dry cell mass and 1125 
mg/l Nef protein was achieved in the E. coli cultivation (Vermasvuori et al., 2009). P. 
pastoris was also cultured in fed-batch mode in 3.5 l stirred-tank bioreactor and the 
cultivation time was about 4 days. 140 g/l dry cell mass and 56 mg/l Nef protein was 
achieved in the P. pastoris cultivation (Sirén et al., 2006). Drosophila S2 insect cell 
line was cultured in batch mode in 5 l stirred-tank bioreactor and the cultivation time 
was about 4 days. Nef titer in Drosophila S2 culture was 6 mg/l (Vermasvuori et al., 
2009).  
 
The purification procedures (presented in Figure 18) were different for GST-Nef 
(intracellular) and His(6)-Nef (extracellular) products.  
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Figure 18. The production and purification procedures of recombinant Nef. 
Procedure A is for GST-Nef that was produced in E. coli and procedure B was 
used for His(6)Nef, produced in P. pastoris and in Drosophila S2 
 
The total purification yields varied from 6 to 24 mass-%. The E. coli Nef purification 
yield was burdened by the fact that the Nef protein was not secreted to the growth 
medium (resulting in the necessity of yield-lowering cell disruption), inclusion body 
formation (as seen in gels after disruption; data not shown) and the necessity of a 
two-step chromatographic separation. In case of the extracellularly-producing 
systems (P. pastoris and Drosophila S2) additionally concentration by ultrafiltration 
was applied. Primary purification was performed by affinity chromatography. The 
Drosophila S2 Nef capture and purification was disturbed by other host cell 
produced histidine-rich proteins, which have affinity towards the Ni-NTA resin used. 
This can also be observed in a low purity achieved after the chromatographic step. 
Combining the total purification yields, the bioreactor productivities and the goal of 
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100 mg of protein in one batch resulted in calculated production volumes of 1.5 l (E. 
coli), 7.4 l (P. pastoris), and about 260 l (Drosophila S2). 
 
The production and primary purification results are summarized in Table 21 
(Vermasvuori et al., 2009). 
 
Table 21. Data of the production and primary purification of Nef protein 
produced in E. coli, P. pastoris and Drosophila S2 cells (Vermasvuori et al., 
2009).  
 E. coli P. pastoris Drosophila S2 
Pre-culture time (h) 20 22 72 
Mode of production culture fed-batch fed-batch batch 
Temperature (°C) 37 30/10 28 
pH 7.5 5 6.2 – 6.5 
DOT minimum (% of air saturation) >30 >30 ~ 50 
Aeration, vvm (l/l/min) 2 – 2.5 1 – 2 N/A 
Production culture time (h) 25 93 96 
Final cell dry weight (dry g/l)        
or cell count (million cells/ml) 
31 141 19 
Final working volume (liter) 2.4 3.4 2.4 
Nef concentration at end of culture 
(mg/l final volume) 
1125 56 6 
Nef volumetric productivity 
(mg/l/h) 
44.3 0.6 0.1 
Purification yield (% of Nef in      
the production broth) 
6.1 24.1 6.5 
Purity (% of the total protein    
mass in the product) 
~ 90 ~ 80 ~ 40 
N-terminal sequence GSMGGKWS (EA)EFMGGKWS RSPWMGGKWS 
Measured mass by Maldi-TOF MS 
(Da) 
23104 24114 24414 
Calculated mass (Da) 22870 23825/24025 24075 
Required production volume          
for 100 mg, if one batch (l) 
1.5 7.4 257 
 
 
4.2 Manufacturing cost in the base case 
 
In the base case, the production goal was set to 100 mg of purified Nef protein. The 
required batch volume was calculated from the titer and from the purification yield; 
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for E. coli the required batch volume was 1.5 l, for P. pastoris 7.4 l and for 
Drosophila S2 257 l (Table 21).  
 
The techno-economical analysis of the manufacturing costs in Nef protein 
production was structurally divided into three phases: 1) strain/cell line construction, 
2) bioreactor production, and 3) recovery and primary purification. The cost 
categories were materials, labor and rental expenses of the equipment. The direct 
operating costs (material and labor costs) were estimated based on the actual 
consumption in the research work (Vermasvuori et al., 2009). The utilities (e.g. 
steam and electricity), indirect operating costs (i.e. maintenance, insurances, taxes 
and general utilities) and depreciation of equipment were assumed to be included in 
the equipment rental expenses. 
 
Material expenses were calculated based on the actual consumption in laboratory 
research work. Materials consisted of genetic engineering tools, culture media 
(including gases), additives (e.g. pH control), chromatography resins, buffers and 
disposable equipment such as sterile filters.  
 
Equipment costs were calculated making the assumption that for the one production 
batch the equipment would be rented from a contract manufacturing organization 
and the costs were thus estimated based on the time the equipment was needed. In 
the needed time, also the sterilization times were included. The rental prices varied 
from 3.5 €/h to 10 €/h. The rented equipment was assumed to be in larger scale 
than the equipment used in the described laboratory process (Vermasvuori et al., 
2009).  
 
Cost of labor was calculated based on the actual working hours spent. As the 
working hours were divided into a longer period of time, the actual hours were 
added together and divided to man days so that one man day presents 8 hours 
work load. Man day (eight man hours) cost 429 €/day was used in calculations. 
 
Fixed cost and cost of quality control were not considered in the calculations as 
these costs were assumed to be virtually equal for all three systems. Licensing 
costs and royalties (IPR costs) were not included either. 
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4.2.1 Strain/Cell line development 
 
The E. coli Nef-protein producing strain was received from FIT Biotech Oyj Plc 
(Finland), but it was estimated that the development of the construct would have 
taken 80 – 160 man hours during 30 – 40 working days and the material costs of 
the genetic engineering tools used in the strain/cell line development phase were 
400 €.  
 
The development of the P. pastoris construct took 120 – 160 man hours in 30 – 40 
working days and the material costs were 2 156 € (Sirén et al., 2006).  
 
The development of the stable Drosophila S2 cell line took 120 – 240 man days in 
45 – 60 working days and the material costs of genetic engineering tools used in 
the development were 1 361 € (Vermasvuori et al., 2009). 
 
Table 22. The material and labor expenses of the strain/cell line development of 
Nef-hosts. 
Strain/cell line development 
E. coli         
(€) 
P. pastoris 
(€) 
Drosophila S2 
(€) 
Labor costs 3 214 7 499 9 641 
Material costs 400 2 156 1 361 
TOTAL 3 614 9 655 11 002 
 
4.2.2 Production  
 
The material cost of the production was scaled to production of 100 mg Nef protein 
from the actual consumption in the laboratory scale research work. The prices of 
the materials were taken from the Sigma-Aldrich (Sigma-Aldrich Inc., USA). 
 
The equipment costs of the production was calculated based on the specific 
equipment rental price (€/h) and the time the equipment was assumed to be needed 
(e.g. the bioreactor that was used for the E. coli cultivation was needed for 25 hours 
cultivation time plus 4 hours for sterilization, loading and emptying). 
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The labor costs were calculated from the man days (eight man hours, 429 €/day) 
used in production, e.g. in the E. coli system, in production phase two man days 
were used. 
 
4.2.2.1 Nef production in E. coli system 
 
The materials consisted of inoculum and fermentation media, as well as of fed-
batch substrate solution and of additived such as isopropyl-ß-D-
thiogalactopyranoside (IPTG) used for induction and ammonium solution used in pH 
control. Trace element solution was added to media and feeding solution. Detailed 
production procedure data is presented by Vermasvuori et al. (2009). Equipment in 
production included inoculum equipment (shake flasks) and a bioreactor. For 
cleaning and sterilization, a rental price was given. In production, two man days 
were used. The production step manufacturing costs are presented in Table 23. 
 
Table 23. The material, equipment rental and labor expenses of the production 
of Nef in 1.5 l E. coli cultivation. 
 
Expense          
€/ unit 
Amount for 
1.5 l 
Total 
(€) 
Materials      
Trace element solution (TES) 3.84 €/l    
Inoculum medium incl. TES 2.73 €/l 0.12 l 0.33 
Fermentation medium incl. TES 2.72 €/l 1.08 l 2.94 
Fed-batch feeding solution incl. TES 9.25 €/l 0.21 l 1.94 
IPTG 40.00 €/g 0.35 g 14.00 
25 % ammonium solution 14.50 €/l 0.04 l 0.58 
     20 
Equipment      
SIP/CIP/Autoclave 3.50 €/h 4 h 14 
Inoculum equipment 4.50 €/h 20 h 90 
Bioreactor (2l) 7.50 €/h 25 h 188 
     292 
Labor      
Labor  429 €/day 2 days 858 
     858 
      
TOTAL     1 169 
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The scaled material costs of the production in E. coli system were 20 €, the 
equipment rental costs were 292 € and the labor expenses 858 €. Total 
manufacturing cost of the production was about 1 200 k€. In production step, the 
materials were only 1.7 % of the manufacturing costs and labor expenses were 73 
% of the costs. The most expensive cost item in materials was the IPTG that was 
used for inducing the protein production.  
 
4.2.2.2 Nef production in P. pastoris system 
 
The materials consisted of inoculum and fermentation media, as well as of 
substrate solutions for glycerol and methanol fed-batch phases and of ammonium 
solution used in pH control. Trace element solution was added to media and feeding 
solutions. Detailed production procedure data is presented in Sirén et al. (2006). 
Equipment in production included inoculum equipment (shake flasks) and a 
bioreactor. For cleaning and sterilization, a rental price was given. In production, 3.5 
man days were used.  
 
The material, equipment rental and labor expenses (i.e. production step 
manufacturing costs) are presented in Table 24. 
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Table 24. The material, equipment rental and labor expenses of the production 
of Nef in 7.4 l P. pastoris cultivation. 
 
Expense       €/ 
unit 
Amount for  
7.4 l 
Total 
(€) 
Materials      
Trace element solution (TES) 20.45 €/l 0.02  0.35 
Inoculum medium  31.97 €/l 0.43 l 13.74 
Fermentation medium 6.94 €/l 3.87 l 26.85 
Fed-batch glyserol solution incl. TES 53.90 €/l 0.32 l 17.38 
Fed-batch methanol solution incl. TES 29.30 €/l 1.50 l 44.08 
25 % ammonium solution 14.50 €/l 0.34 l 4.99 
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Equipment      
SIP/CIP/Autoclave 3.50 €/h 4 h 14 
Inoculum equipment 4.50 €/h 22 h 99 
Bioreactor (9l) 7.50 €/h 93 h 698 
     811 
Labor      
Labor  429 €/day 3.5 days 1502 
     1 502 
      
TOTAL     2 419 
 
The scaled material costs of the production in P. pastoris system were 107 €, the 
equipment rental costs were 811 € and the labor expenses 1 502 €. Total 
manufacturing cost of the production was about 2 400 €. In production step, the 
materials were only 4.4 % of the manufacturing costs and the labor expenses 
covered 62 % of the costs. In the material costs, the methanol feeding solution was 
the most expensive cost item (the methanol price used in calculations was 29 €/l). 
 
4.2.2.3 Nef production in Drosophila S2 system 
 
The materials consisted of fermentation media and of oxygen that was used to 
enrich the inlet air. Detailed production procedure data is presented in Vermasvuori 
et al. (2009). Equipment in production included inoculum equipment (roller bottles) 
and a bioreactor. For cleaning and sterilization, a rental price was given. In 
production, 4.5 man days were used.  
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The material, equipment rental and labor expenses (i.e. production manufacturing 
costs) of production in 257 l Drosophila S2 system are presented in Table 25. The 
fermentation medium price was estimated from list price (40 €/l) assuming a bulk 
reduction.  
 
Table 25. The material, equipment rental and labor expenses of the production 
of Nef in 257 l Drosophila S2 cultivation. 
 
Expense       
€/ unit 
Amount for 
257 l 
Total 
(€) 
Materials      
Fermentation medium 30.00 €/l 257.00 l 7 710 
Oxygen 1.08 €/m3 16.70 l/l/h 447 
     8 155 
Equipment      
SIP/CIP/Autoclave 3.50 €/h 4 h 14 
Inoculum equipment 4.50 €/h 72 h 324 
Bioreactor (260l) 10.00 €/h 96 h 960 
     1 298 
Labor      
Labor  429 €/day 4.5 days 1 931 
     1 931 
      
TOTAL     11 384 
 
The scaled material costs of the production in Drosophila S2 system were 8155 €, 
the equipment rental costs 1298 € and the labor expenses 1931 €. Total 
manufacturing cost of the production was about 11 400 €. The materials were 72 % 
of the manufacturing costs, the labor equipment expenses 11 % and the labor costs 
covered 17 % of the costs. The scale in Drosophila S2 production was much larger 
than the scale in microbial cultivations, and also the cost breakdown is different. In 
smaller scales, the labor expenses were in more significant position than in this 
larger scale. The differences in the costs breakdown are also explained by the 
differences in the material expenses (13 €/l for E. coli, 14 €/l for P. pastoris and 32 
€/l for Drosophila S2). 
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4.2.3 Purification 
 
The material cost of the purification phase was scaled similarly as in the production 
phase to represent production of 100 mg Nef protein. The protein amount in 
beginning of the purification was for E. coli system 3 260 mg, for P. pastoris 417 mg 
and for Drosophila S2 1 540 mg. 
 
The material prices were taken from Sigma and Amersham Biosciences (GE 
Healthcare/Amersham Biosciences, USA) catalogs. The consumable (clarification 
and sterile filters) prices were from Millipore (Millipore, USA) and Pall (Pall, USA). 
The equipment costs of the purification phase were calculated based on the specific 
equipment rental price (€/h) and on the time the equipment was assumed to be 
needed. The labor costs were calculated from the man days (429 €/day) used in 
purification. Detailed purification procedure data for E. coli and Drosophila S2 is 
presented in Vermasvuori et al. (2009) and for P. pastoris in Sirén et al. (2006). 
 
4.2.3.1 Nef purification in E. coli system 
 
The materials consisted of chromatography resins and buffers and of consumables 
such as sterile filters and concentration units. Equipment in purification included 
only laboratory scale pump for chromatography (price not given) and filtration and 
centrifugation devices. In purification, three man days were used. The material, 
equipment rental and labor expenses are presented in Table 26. 
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Table 26. The material, equipment rental and labor expenses of the purification 
phase of Nef-protein in 1.5 l E. coli cultivation. 
 
Expense           
€/ unit 
Amount for  
1.5 l 
Total 
(€) 
Materials      
Glutathion sepharose resin 200.00 €/10ml 15 ml 300.00 
Glutathion elution buffer 8.44 €/g 0.30 g 2.53 
Thrombin enzyme 0.17 €/u 150 u 24.75 
Benzamide sepharose 8.96 €/ml 2.14 µl 0.02 
0.2 µm filter 4.50 €/piece 1 piece 2.25 
Amicon ultra-15 concentration unit 10.00 €/piece 4 pieces 40.00 
     370 
Equipment      
Filtration / Centrifugation device            
for 1.5 l cultivation 
4.5 €/h 3.7 h 17 
     17 
Labor      
Labor  429 €/day 3 days 1 287 
     1 287 
      
TOTAL     1 673 
 
The scaled material costs of the purification in E. coli system were 370 €, the 
equipment rental costs were 17 € and the labor expenses 1287 €. Total 
manufacturing cost of the purification phase was about 1 700 €. In purification step, 
the equipment expenses were only 1 % of the manufacturing costs and labor 
expenses covered 77 % of the costs. The most expensive cost item in materials 
was the glutathion sepharose resin that here was handled as single-use, but that in 
larger scale would be used several times.  
 
4.2.3.2 Nef purification in P. pastoris system 
 
The materials consisted of chromatography resins and buffers and of consumables 
such as concentration units. Equipment in purification included only laboratory scale 
pump for chromatography (price not given) and of filtration and centrifugation 
devices. In purification, two and half man days were used.  
 
The scaled material costs of the purification in P. pastoris system were 196 €, the 
equipment rental costs were 43 € and the labor expenses 1 073 €. Total 
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manufacturing cost of the purification phase was about 1 300 €. The material, 
equipment rental and labor expenses are presented in Table 27. 
 
Table 27. The material, equipment rental and labor expenses of the purification 
phase of Nef-protein in 7.4 l P. pastoris cultivation. 
 
Expense           
(€/unit) 
Amount for  
7.4 l 
Total 
(€) 
Materials      
Ni-NTA resin  14.45   €/ml 10.4 ml 150.56 
Imidazole for elution buffer  0.29   €/g 17.0 g 4.97 
Amicon ultra-15 concentration unit  10.00   €/piece 4 pieces 40.00 
     196 
Equipment      
Filtration / Centrifugation device            
for 7.4 l cultivation 
4.50 €/h 9.5 h 43 
     43 
Labor      
Labor  429 €/day 2.5 days 1073 
     1 073 
      
TOTAL     1 311 
 
In purification phase, the equipment expenses were only 3 % of the manufacturing 
costs and labor expenses covered 82 % of the costs. The most expensive cost item 
in materials was again the affinity chromatography resin that here was handled as 
single-use, but that in larger scale would be used several times.  
 
4.2.3.3 Nef purification in Drosophila S2 system 
 
The materials consisted of chromatography resins and buffers and of consumables 
such as concentration units. Equipment in purification included filtration and 
centrifugation devices. In purification, two and half man days were used.  
 
The scaled material costs of the purification in Drosophila S2 system were 582 €, 
the equipment rental costs were 71 € and the labor expenses 1 073 €. Total 
manufacturing cost of the purification phase was about 1 700 €. The material, 
equipment rental and labor expenses are presented in Table 28. 
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Table 28. The material, equipment rental and labor expenses of the purification 
phase of Nef-protein in 257 l Drosophila S2 cultivation. 
 
Expense           
€/unit 
Amount for 
257 l 
Total 
(€) 
Materials      
Ni-NTA resin 14.45 €/ml 38.6 ml 557.24 
Imidazole for elution buffer 0.29 €/g 17.01 g 4.97 
Amicon ultra-15 concentration unit 10 €/piece 2 pieces 20.00 
     582 
Equipment      
Sterile Filtration / Centrifugation 
device for 250l 
4.50 €/h 3.5 h 16 
Concentration (4 m3) 4.50 €/h 4 h 18 
Concentration (0.1 m3) 5.50 €/h 2 h 11 
Diafiltration (0.1 m3) 6.50 €/h 4 h 26 
     71 
Labor      
Labor  429 €/day 2.5 days 1 073 
     1 073 
      
TOTAL     1 725 
 
In purification phase, the equipment expenses were only 4 % of the manufacturing 
costs and labor expenses covered 62 % of the costs. The most expensive cost item 
in materials was again the affinity chromatography resin that here was handled as 
single-use, but that in reality would be used several times. As the scale here is 
larger than in the microbial productions, the significance of the labor expenses is 
lower. Still, the labor expense is the most important cost item.  
 
4.2.4 Total manufacturing cost 
 
The costs of producing 100 mg Nef protein using the three expression host systems 
are summarized in Table 29. 
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Table 29. Manufacturing costs of producing 100 mg Nef protein using three 
different host systems 
 
E. coli         
(€) 
P. pastoris 
(€) 
Drosophila S2 
(€) 
Strain/cell line development    
Labor costs 3 214 7 499 9 641 
Material costs 400 2 156 1 361 
Production    
Material costs 20 107 8 155 
Equipment costs 292 811 1 298 
Labor costs 858 1 502 1 931 
Purification    
Material costs 370 196 582 
Equipment costs 17 43 71 
Labor costs 1 287 1 073 1 073 
TOTAL 6 458 13 387 24 112 
 
Quite expectedly, the E. coli system was found to be the lowest cost system 
(manufacturing cost about 6 500 €), whilst the manufacturing costs of the P. 
pastoris and Drosophila S2 systems were about two (13 400 €) and almost four (24 
100 €) times higher. Generally, the P. pastoris and Drosophila S2 systems were 
burdened by clearly longer strain/cell line construction phases compared to E. coli 
system. The Drosophila S2 system was also burdened by a very expensive 
production step, mainly due to a higher cost of raw materials (i.e. growth medium 
and pure oxygen gas) and a longer culture time (compared to E. coli). The cost 
distribution of the manufacturing cost in respect to the different steps is shown in 
Figure 19. 
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Figure 19. Cost distributions of producing 100 mg Nef protein using E. coli, P. 
pastoris and Drosophila S2 in respect to the different steps.  
 
Comparing different cost factors (i.e. labor, material and equipment) of the 
manufacturing costs, labor costs were found to be in range of 80 % of the 
manufacturing costs for the microbial systems and about 50 % for the Drosophila 
S2 system (see Figure 20). Moreover, when produced commercially, the possible 
license payments and royalties related to the use of strains/cell lines and/or vectors 
must be added to the manufacturing costs. 
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Figure 20. Cost distributions of producing 100 mg Nef protein using E. coli, P. 
pastoris and Drosophila S2 in respect to the different cost factors. 
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4.3 Manufacturing cost of the production step - the equal titer case 
 
The manufacturing costs of the 100 mg Nef protein production were strongly 
dependent on the titers and yields of the practical experiments. If the systems were 
optimized, titers of the yeast and insect cell systems could surely be increased. 
Therefore the manufacturing cost of the production step was calculated assuming a 
constant titer and bioreactor working volume (10 liter). Material and equipment 
rental prices were re-calculated for this scale, but the labor costs were kept equal 
on both production volumes for all three production systems. 
 
4.3.1 Nef production in E. coli system 
 
For E. coli system, the production volume in original case was 1.5 l and in equal titer 
case 10 l. Both these scales are small/bench scale, and therefore the equipment 
and labor expenses were same in both scales. Also the material prices were same, 
only the amounts the materials were used were changed in this larger scale. The 
expenses are presented in Table 30.   
 
Table 30. The material, equipment rental and labor expenses of the production 
of Nef in 10 l E. coli cultivation. 
 
Expense       
€/ unit 
Amount for  
10 l 
Total 
(€) 
Materials      
Trace element solution (TES) 3.84 €/l    
Inoculum medium incl. TES 2.73 €/l 0.83 l 2.26 
Fermentation medium incl. TES 2.72 €/l 7.46 l 20.28 
Fed-batch feeding solution incl. TES 9.25 €/l 1.45 l 13.41 
IPTG 40.00 €/g 2.38 g 95.32 
25 % ammonium solution 14.50 €/l 0.27 l 3.84 
     135 
      
Equipment     292 
Labor      858 
TOTAL     1 285 
 
The total bioreactor step manufacturing costs was about 1 300 €. As the material 
expenses were the only one increased in the larger scale, also the material cost 
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share of the total manufacturing costs was increased. Still, the material expenses 
are only 10.5 % of the total manufacturing cost. 
 
4.3.2 Nef production in P. pastoris system 
 
Also in P. pastoris system, the equipment and labor expenses were same in both 
scales (7.5 and 10 l). Also the material prices were same, only the amounts the 
materials were used were changed in this slightly larger scale. The expenses are 
presented in Table 31.  
 
Table 31. The material, equipment rental and labor expenses of the production 
of Nef in 10 l P. pastoris cultivation. 
 
Expense       
€/ unit 
Amount for   
10 l 
Total 
(€) 
Materials      
Trace element solution (TES) 20.45 €/l 0,02 l 0,47 
Inoculum medium  31.97 €/l 0,58 l 18,57 
Fermentation medium 6.94 €/l 5,23 l 36,28 
Fed-batch glyserol solution incl. TES 53.90 €/l 0,44 l 23,48 
Fed-batch methanol solution incl. TES 29.30 €/l 2,03 l 59,57 
25 % ammonium solution 14.50 €/l 0,46 l 6,74 
     145 
      
Equipment     811 
Labor     1 502 
TOTAL     2 419 
 
The total bioreactor step manufacturing costs was about 2 400 €. Similarly to the E. 
coli cultivation, also here the material expenses were the only one increased in the 
larger scale. Still, the material expenses are only 6 % of the total (compared to 4.4 
% in 7.5 liter scale).  
 
4.3.3 Nef production in Drosophila S2 system 
 
The insect cell cultivation was downscaled from 257 l to 10 l for this equal titer case. 
Therefore the price of the medium was higher, but on the other hand, the rental 
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price of the bioreactor was lower. The labor expenses were equal in both scales. 
The expenses are presented in Table 32. 
 
Table 32. The material, equipment rental and labor expenses of the production 
of Nef in 10 l Drosophila S2 cultivation. 
 
Expense       
€/ unit 
Amount for   
10 l 
Total 
(€) 
Materials      
Fermentation medium 40.00 €/l 10.00 l 400 
Oxygen 1.08 €/m3 16.70 l/l/h 17 
     417 
Equipment      
SIP/CIP/Autoclave 3.5 €/h 4 h 14 
Inoculum equipment 4.5 €/h 72 h 324 
Bioreactor (10 l) 7.5 €/h 96 h 720 
     1 058 
      
Labor      1 931 
TOTAL     3 406 
 
The total bioreactor step manufacturing costs was about 3 400 €. In this smaller 
scale, the material expenses were 12 %, the equipment 31 % and the labor 
expenses 57 %. Therefore, the cost distribution of the production in this smaller 
scale resembles more the cost breakdown in microbial hosts where the labor 
expenses dominate the costs.  
 
4.3.4 Production step manufacturing costs 
 
The material costs of the production step were scaled to production volume of 10 
liter. The scaled material costs of the E. coli system were 135 €, of the P. pastoris 
system 145 € and of the Drosophila S2 system 417 €. The equipment costs of the 
production and purification phases were calculated similarly as on the analysis 
above. For E. coli, the equipment rental time and prices were the same for 1.5 l and 
10 l batch (292 €). Same applies to the P. pastoris system, were the volumes were 
7.5 l and 10 l with equipment costs of 811 €. For Drosophila S2 system the 
bioreactor rental price was lower for the 10 l bioreactor as compared to the 258 l 
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bioreactor (equipment cost were decreased from 1 298 € to 1 058 €). The labor 
expenses were equal in both scales for all hosts.  
 
Applying this assumption of the same titer and production volume, the 
manufacturing costs of the production (bioreactor) step for E. coli, P. pastoris and 
Drosophila S2 were about 1 300 €, 2 400 €, and 3 400 €, respectively. The 
manufacturing costs of 10 l cultivation for each host are presented in Table 33 and 
in Figure 21. 
 
Table 33. Costs of production (bioreactor) step of Nef protein on a 10-liter 
bioreactor scale. 
 E. coli         
(€) 
P. pastoris 
(€) 
Drosophila S2 
(€) 
Production    
Material costs 135 145 417 
Equipment costs 292 811 1058 
Labor costs 857 1500 1928 
TOTAL 1283 2455 3404 
 
The almost two-fold manufacturing cost difference between the bacterial and yeast 
system was mainly due to the difference in cultivation time (E. coli about one day 
and P. pastoris almost four days). This naturally reverberated in higher equipment 
rental costs and labor costs. The most expensive raw materials with the microbial 
systems were IPTG with the E. coli system (70 % of total material costs) and 
methanol with the P. pastoris system (41 % of total material costs). Ten liter P. 
pastoris cultivation consumes almost two liters of methanol.  
 
The manufacturing cost difference between the yeast and insect cell systems was 
mainly due to the complex, more expensive growth medium needed for the 
Drosophila S2 cultivation and a slightly longer cultivation time (including the pre-
culture). 
 
On this scale, the labor cost was the most significant cost factor (57 – 67 % of 
manufacturing costs) in each system, whereas the influence of the material costs 
were very low (6 – 12 % of manufacturing costs) (Figure 21). 
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Figure 21. Cost distributions of the production cultivation (bioreactor) step using 
the E. coli, P. pastoris and Drosophila S2 host systems at a constant bioreactor 
working volume of 10 liters.  
 
4.4 Conclusion 
 
Recombinant proteins can be produced in a variety of different hosts, microbial, 
mammalian and insect cell systems. In cases where no post-translational 
modifications are required, also E. coli is a low cost alternative for production. Here 
three different hosts (E. coli, P. pastoris and Drosophila S2) were studied and the 
manufacturing costs of small scale (100 mg in one batch) production of a diagnostic 
recombinant protein (HIV-1 Nef) were compared.  
 
As was to be expected, the microbial systems (E. coli and P. pastoris) had 
significantly lower total manufacturing costs than the insect cell system. Table 29, 
Figure 19 and Figure 20 show the manufacturing costs of 100 mg purified Nef-
protein when the hosts had different titers and purification yields. The most 
significant difference between the two microbial system manufacturing costs was a 
result of a much longer strain construction time with the P. pastoris system (strain 
development costs of E. coli 3 600 € and of P. pastoris 6 900 €, Table 22).  Omitting 
the strain construction costs, the microbial systems were cost-wise fairly 
comparable. In this case, the combined production and purification manufacturing 
costs for the E. coli and P. pastoris systems were about 2 800 € and 3 700 €, 
respectively.  
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The cell line construction expenses were even greater for the insect cell system 
(11 000 €, Table 22). The manufacturing costs for the Drosophila S2 system were 
also clearly higher compared to the microbial systems (combined production and 
purification 13 100 €). The higher manufacturing costs were a result of i) the lowest 
total Nef titer resulting in the need of a larger working volume, ii) the longest 
cultivation time, and iii) the need of a complex (expensive) growth medium. 
 
On the scale of 100 mg purified protein and of bioreactor working volume less than 
10 liters, the role of the material and equipment costs are relatively insignificant. In 
the microbial systems the labor costs accounted for 75 and 83 % of the total costs. 
In insect cell system the bioreactor working volume was notably larger (247 l) and 
also the cost distribution was slightly different, but the labor costs were still the 
major manufacturing cost (labor costs accounted for 52 % and material costs 42 
%). For production on a bench/small pilot scale, this distribution of costs is fairly 
typical. In fact, the cost distribution as a function of scale presented by Rouf et al. 
(2000) is quite similar.  
 
When comparing the three host systems assuming an equal titer and equal 
bioreactor working volume 10 l, the economical advantage of the microbial systems 
is still obvious (Table 33 and Figure 21) even though the share of the material costs 
for the Drosophila S2 system was now clearly reduced; labor costs 57 % and 
material costs 12 % of the manufacturing cost. However, here only the bioreactor 
step was considered. If also the capture and purification steps were included in this 
equal titer case, the downstream processing costs of E. coli and P. pastoris 
products would have increased, and of Drosophila S2 product would have 
decreased as compared to the base case.  
 
From a technical perspective the three systems have different advantages and 
disadvantages. The E. coli system had the lowest costs of the studied systems. This 
was mainly due to fast growth rate and high Nef volumetric productivity. Generally, 
the E. coli system is easy to scale-up and it is highly reproducible. Similar opinions 
have previously been presented e.g. by Andersen and Krummen (2002), Schmidt 
(2004) and Walsh (2006). Disadvantages of the E. coli system include side-product 
production (e.g. endotoxins and proteases), intracellular production of recombinant 
proteins and formation of inclusion bodies. When producing more complex proteins 
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the lack of a post-translational machinery limits the use of E. coli (Jana and Deb, 
2005; Sarramegna et al., 2003). 
 
The specific productivity of P. pastoris is usually rather low. This, however, is often 
compensated by the high cell densities achieved in P. pastoris cultivations (Cha et 
al., 2005). The P. pastoris production protocols are straight-forward resulting in 
good reproducibilities. Scale-up is as easy as with E. coli, except for the fact that 
methanol is needed in high quantities and this can require some additional technical 
solutions. General disadvantages of the P. pastoris system include slow growth, 
significant strain and vector kits costs, and production of host cell proteases. When 
moving to commercial production, the license and royalty costs in regard to the 
strains and vectors must also be considered. 
 
The insect cell systems are gaining popularity, especially for the production of 
complex (therapeutic) proteins (Ikonomou et al., 2003; Walsh, 2003). In comparison 
to mammalian cells, the ease of culture and higher expression levels are considered 
advantages of the insect cell systems. On the other hand, when compared to 
microbial cells, the insect cells grow very slow and the production levels are usually 
mediocre or low. When planning commercial use of the Drosophila S2, the used 
vectors result in additional IPR costs. 
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5 Manufacturing cost of monoclonal antibody production in 
stirred tank and hollow fiber processes  
 
 
The manufacturing cost in production of a diagnostic monoclonal antibody in 
different bioreactor was analyzed. The equipment used in the analysis were stirred 
tank bioreactor (STR) equipped with a spin filter and a hollow fiber bioreactor (HFB). 
Both were operated as perfusion process.  
 
The performances of the STR and the HFB in monoclonal antibody production have 
been reviewed e.g. by Yang et al. (2004) but they did not include economical 
analysis in their study. Analyses of the manufacturing costs based on the bioreactor 
type used have been previously presented for conventional STR and for disposable 
bioreactors (e.g. Farid et al., 2005a, 2005b; Novais et al., 2001, 2005b), but no cost 
analyses of the STR versus HFB have been published. The STR is generally used 
in large scale, as it is easy to scale and operate, but in smaller scale, as in case of 
diagnostic or research monoclonal antibodies, the HFB is also quite frequent 
(Griffiths, 2003; Jain and Kumar, 2008; Valdes et al., 2001; Yazaki et al., 2001). The 
HFB is especially good alternative for hybridoma cultures (Yang et al., 2004).  
 
In this manufacturing cost comparison the scale used was 85 g of unpurified Mab 
that was to be produced in 60 days. Purification yield was assumed to be 55 % 
resulting to 47 g of purified Mab. According to Farid et al. (2005b), 45 g of Mab is 
sufficient to Phase I clinical trials. The purification procedure used for both 
production methods was the same, and it was assumed to be as described in e.g. 
Farid et al. (2005b) and Sommerfeld and Strube (2005).  
 
The manufacturing costs of the production phase were calculated from investment 
and operating costs. The costs of the purification phase are estimated from the cost 
distribution (cost ratio of upstream and downstream processes) presented by 
Sommerfeld and Strube (2005).  
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5.1 Monoclonal antibody production data 
 
5.1.1 Production phase 
 
The antibody was intended to be produced either in stainless steel STR bioreactor 
with a spin-filter or in several HF cartridges (Figure 22). In the STR the cells are 
grown outside the filter and product is harvested from inside the filter. In the HFB 
the cells are grown in the intracapillary space and the product is harvested from the 
extracapillary scape, outside the membrane tubes.  
 
Medium
Oxygenated medium
Product harvest Product harvest
impeller
Oxygen
Rotating 
filter
A B
cells cells
 
Figure 22. A Schematic picture of the processes used A) a stirred-tank bioreactor 
with a spin filter B) hollow fiber bioreactor. 
 
The production goal was set to 46 g in 60 days. With purification yield of 55 % the 
fermentation titer was set to 85 g. The total annual production time is assumed to 
include five 60 days periods, i.e. the total produced Mab amount is 425 g that 
results to 234 g of purified Mab.  
 
The FiberCell Systems Inc. (USA) hollow fiber cartridge 4300-C2018 High MWCO 
(Anon., 2008a) is supposed to be used in this hypothetical study. Hollow fiber 
bioreactor is operated first week as perfusion culture, where the fresh medium is 
supplied to the cartridge and used medium is withdrawn, but no actual harvest is 
made. After the week’s growth period, the cells are grown to concentration of 108 
cells/ml. In continuous cultivation, the cartridges extracapillary space (ECS) is 
  91 
harvested every two days and also some cells are removed within the harvest. The 
harvest volume is 70 ml/cartridge (same as the cartridges ECS volume) and 400 mg 
Mab is assumed to be harvested. Harvest protocol is the same as used in FiberCell 
Systems Inc. (USA) products (Anon., 2008a) 
 
According to Davis (2007), the HFB culture normally runs from four to six months, 
and the culture ends because either the cells may lose the productivity or the 
flowpath becomes partially blocked. Both of these happen usually because of the 
accumulation of dead cells and cell debris in the cartridge. In ProstaScint production 
the HFB hybridoma culture lasted 60 days and in Humaspect production the human 
cell line culture in HFB lasted 10 weeks (Farid, 2006).  
 
The literature derived parameters of the perfusion (by spin filter device) cultures of 
hybridoma cells are presented in Table 34 (Castilho and Medronho, 2002).  
 
Table 34. Performances of hybridoma cultivations in STR with spin filters (from 
Castilho and Medronho, 2002)  
Cell line Product Reacto
r 
volume 
(l) 
Max 
perfu-
sion rate 
(1/d) 
Culti-
vation 
time 
(d) 
Max 
viable cell 
conc. (106 
cells/ml) 
Reference 
Hybridoma IgG 1.2 2.0 37 15 
(Heine et 
al., 2000) 
Hybridoma 
and myeloma 
IgM and 
IgG 
7 to 
500 
1.2 30 >10 
(Deo et al., 
1996) 
Hybridoma -- 175 0.5 
At least 
8 
2.8 
(Yabannavar 
et al., 1994) 
 
The perfusion process is generally first cultivated 8 – 10 days in batch mode for 
growing the cells to production concentration (Deo et al., 1996). After this, fresh 
medium is fed to the reactor with perfusion rate ranging from 0.5 to 2 reactor 
volumes (RV) per day. Antibody is collected from the used medium continuously.  
 
The performance of the HFB system was estimated from FiberCell Systems Inc. 
(USA) product overview (Anon., 2008a) and from the protocol presented by Davis 
(2007). The cell concentrations presented by FiberCell Systems Inc. (Anon., 2008a) 
and a specific productivity of 20 pg/cell/day (Andersen and Krummen, 2002) was 
used in calculations. Same specific productivity is used also in STR calculations, 
although in some cases, higher specific productivities can be achieved in HFB 
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compared to STR (Yang et al., 2004). The performance of the STR system and of 
the hybridoma cell line was estimated from Deo et al., (1996). The performance 
data (estimated and calculated) is presented in Table 35. 
 
Table 35. Assumptions made in the STR and HFB production 
 STR with spin filter HFB (data per one 
cartridge) 
Cartridge ECS 
volume  
-- 70 ml 
Inoculum 105 cells/ml 108 cells 
Final cell 
concentration 
107 cells/ml 108 cells/ml or                     
1010 cells/cartridge 
Specific productivity 20 pg/cell/day 20 pg/cell/day 
Productivity 0.2 mg/ml/day 400 mg/every 2nd day 
Medium 
consumption 
1 RV/first week,                  
then 1.2 RV/day 
3.75 l/first week, then 2 l/day 
Harvest volume 1.2 RV/day 70 ml/every 2nd day 
Harvest 
concentration 
0.17 mg/ml 5.7 mg/ml 
Culture runtime 29 days a 60 days b 
a includes a 8 days batch period for cell growth, no harvest in this period 
b includes a 7 days period for cell growth where no harvest is performed  
 
Based on the cultivation data presented in Table 35 and on the goal of 85 g of 
antibody in 60 days, the size of the STR and the number of HF cartridges were 
calculated. As the STR perfusion run was assumed to last 29 days (plus one day for 
bioreactor cleaning and sterilizing), two runs were needed. The used equipment and 
consumables in the antibody production phase are summarized in Table 36. In STR 
option, shake flasks and a 10 l stainless steel bioreactor equipped with internal spin-
filter was used. In HFB option disposable bioreactor was used for inoculum and for 
production, eight 1.2 m2 hollow fiber cartridges (e.g. from Fibercell Systems, Inc, 
USA) were used.  
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Table 36. The equipment and consumables used in antibody production phase. 
Task Equipment Consumables 
 STR  HFB STR HFB 
Inoculum 
cultivation 
Shake flasks --- --- Disposable 
bioreactor 
Production 
cultivation 
10 l stirred-tank 
bioreactor (equipped 
with a spin-filter) 
--- --- 8 x 1.2 m2 HFB 
cartridges 
 
5.1.2 Capture and purification phase 
 
The purification is performed as described in Sommerfeld and Strube (2005) and in 
Farid et al. (2005b): clarification, concentration, capture chromatography (protein 
A), virus inactivation, buffer exchange, ion exchange chromatography, viral 
clearance, buffer exchange, polishing chromatography (HIC) and final filtration. The 
same purification procedure is used for both production methods. The schematic 
figure of the generic purification is presented in Figure 12 in section 2.4.  
 
 
5.2 Manufacturing cost  
 
For comparing the production methods, the manufacturing costs of the product for 
both systems were calculated. The manufacturing cost consists of the direct 
operating costs, indirect operating costs and depreciation of the investment cost. 
 
5.2.1 Investment costs of the upstream processing 
 
For this size of production, no new production site is to be built. Both production 
options are most likely easily fitted to an existing research center or production 
facility and also no actual extension is needed. The equipment is still assumed to be 
bought and installed and also the heating, ventilation and air-conditioning (HVAC) 
issues are updated for therapeutics production. For STR option, also the CIP and 
SIP connections are assumed to be built.  
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The major equipment capital costs of upstream production for the spin filter 
equipped STR option are based on the equipment costs presented by Farid (2005b) 
and Bailey (2009) and presented in Table 37.  
 
Table 37. The equipment capital costs of the upstream production for STR option. 
Equipment Cost Reference 
Shake flasks for inoculum (10 pieces) 200 € Farid (2005b) 
10 l bioreactor and spin-filter 75 000 € Bailey (2009) 
Total equipment cost 75 200 €  
 
The FCI of the upstream processing of the STR option was calculated from the total 
equipment cost presented in Table 37 with Lang’s factor 6 resulting to FCI of 451 
k€. Farid et al., (2005b) used Lang's factor 7 in 200 l bioreactor scale, but here the 
bioreactor is significantly smaller and therefore e.g. the costs of the equipment 
installation are lower. Instrumentation and control, electrical systems, validation and 
utility (SIP and CIP) costs are same on both scales.  
 
For the HFB option, the FCI was calculated from the STR option equipment cost by 
a modified Lang method (see section 3.1.2 for more details) with a Lang’s factor of 
3.6. The resulting investment cost 271 k€ is 40 % lower as compared to the FCI of 
the conventional process as calculated by Novais et al., (2001) and Sinclair and 
Monge (2005b).  
 
Table 38. The fixed capital investment costs of the STR and HFB option 
(equipment cost used was 75.2 k€). 
 Lang's factor FCI 
STR with spin filter 6 451 200 € 
HFB 3.6 270 720 € 
 
5.2.2 Operating costs of the upstream processing 
 
The direct operating costs were calculated from the raw material (medium and 
consumables) and labor expenses. For miscellaneous material (e.g. safety clothing 
etc.) a value of 50 % of the direct raw material costs was used (Farid et al., 2007). 
Utilities included oxygen for inlet air enrichment, CIP water and detergents and 
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steam for sterilization. The oxygen consumption was calculated from the cell 
specific oxygen uptake rate 0.5 pmol/cell/h (Henzler and Kauling, 1993) and from 
the cell density and culture time. Labor costs were calculated assuming two 
employees: Both production equipment are highly instrumented and easily operated 
and because of long cultivation times, few bioreactor turnovers are needed. QCQA 
cost was assumed to be equal to one person’s annual salary. Management cost 
was assumed to be 30 % of one person’s salary. Direct operating cost calculations 
are presented in Table 39. The material and utilities costs are calculated as costs 
per batch and as costs per year (5 HFB cultures and 10 STR batches are cultured 
annually).  
 
Table 39. Upstream direct operating cost calculations. 
  HFB STR 
 €/unit usage 
total      
(€) 
total      
(%) 
usage 
total      
(€) 
total      
(%) 
Raw materials         
Medium 1 6 €/l 880 l 5 280  265 l 1 591  
Consumables        
Roller Bottles  25 €/pc 6 pcs 150     
HF cartridges  800 €/pc 8 pcs 6 400     
Miscellaneous 2   2 640   795  
Utilities        
Oxygen 10 €/m3 906 l 9  789 l 8  
CIP 1.3 €/l    40 l 53  
Steam 0.1 €/kg    10 kg 1  
Total / batch   14 479   2 448  
        
Total raw 
materials 3 
  72 395 31   24 476 13  
Labor 
(monthly) 
4000 € 2 96 000 42  2 96 000 52 
QCQA 4   48 000 21   48 000 26  
Management 5   14 400 6   14 400 8  
TOTAL 
DIRECT 
  230 795   182 876  
1 Medium is supposed to be bought pre-made and sterile. 
2 Miscellaneous is calculated as 50 % of medium costs 
3 Total 5 HFB batches and 10 STR batches 
4 QCQA is calculated as one person’s annual salary 
5 Management is calculated as 30 % of one person’s annual salary 
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Direct upstream operating cost for the HFB process is 231 k€ and for the STR 
process 183 k€. Labor expenses cover 42 % of the direct operating costs of the 
HFB upstream process and 52 % of the STR upstream process. The combined 
labor, QCQA and management costs cover as much as 69 % of the direct operating 
costs of the HFB upstream process and even 87 % of the STR upstream process. 
 
In indirect cost estimation, maintenance, depreciation of the investment, insurances 
and general utilities (i.e. electricity, heating etc) are included. The annual 
maintenance cost was estimated to be 8 000 €. The insurances are assumed to be 
approximately 4 % of the personnel salary. A depreciation period of 5 years and 
interest rate 15 % was used. The general utilities are calculated as 135 €/m2 (Farid 
et al., 2007) using floor area 30 m2. The indirect cost calculations are presented in 
Table 40.  
 
Table 40. Indirect operating cost calculation  
 HFB STR 
Maintenance (estimated) 8 000 € 8 000 € 
Insurances  3 840 € 3 840 € 
Depreciation  80 760 € 134 600 € 
General utilities  4 050 € 4 050 € 
TOTAL INDIRECT COST 96 650 € 150 490 € 
 
Total indirect costs for HFB option are 97 k€ and for STR option 150 k€. The 
investment depreciation covers 84 % of the indirect operating costs of the HFB 
upstream process and 89 % of the indirect operating costs of the STR upstream 
process.  
 
5.2.3 Manufacturing cost for the upstream processing 
 
The total manufacturing cost for the upstream HFB process was 327 k€ and for the 
upstream STR process 333 k€. Although the investment cost of the STR was 
almost double that of the HFB process, the higher material costs (73 k€ versus 24 
k€) made the STR only slightly more expensive as the HFB process. In STR system 
manufacturing cost, the depreciation (40 % of the manufacturing cost) and the labor 
expenses (29 %) were the largest cost items. Also in the HFB system, the largest 
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cost items were labor expenses (29 %) and depreciation expenses (25 %), but the 
material expenses were also significant (22 %). The manufacturing cost distribution 
of the systems is presented in Figure 23.  
 
 
Figure 23. The USP manufacturing cost distribution of the STR and HFB 
processes. Other includes the costs of maintenance, insurances and general 
utilities. 
 
Manufacturing cost per gram of product was calculated by dividing the total 
manufacturing by the produced amount of purified Mab, 234 g. The upstream 
manufacturing cost per gram of product was 1.4 k€/g for both options.  
 
5.2.4 Manufacturing cost for the downstream processing 
 
As has been stated before (see section 3.3.4), the cost of the downstream 
processing (DSP) does not depend as much on the fermentation titer as the 
upstream processing (USP) cost, since most expenses come from the 
chromatography columns, that are designed on mass basis and not on 
concentration basis. However, typical downstream process involves also numerous 
filtration processes that are designed on volume (and concentration) basis. The 
difference in the harvest volume between STR and HFB products is significant (STR 
daily harvest volume 12 l; HFB 70 ml every second day) and therefore the 
investment and operating costs of the HFB downstream system will be lower.  
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Based on the product mass, the downstream manufacturing costs for both HFB and 
STR processes should be almost equal. Sommerfeld and Strube (2005) have 
presented a ratio of the upstream processing costs versus downstream processing 
costs as a function of product titer for monoclonal antibody production, but this 
applies only if the processes are otherwise equal.  
 
For titer of 0.17 g/l (the titer in the STR process), the ratio of USP and DSP costs is 
52 % to 48 % (Sommerfeld and Strube, 2005). Therefore it is safe to estimate, that 
the downstream process costs for the STR process are 308 k€. Although from the 
presentation of Sommerfeld and Strube (2005) it could be assumed that the 
downstream processing costs of the HFB product are higher than the purification 
process costs of the STR product, most likely the opposite is true. As the STR 
product is in lower concentration, it needs an additional concentration step in the 
purification process as compared to the purification process of the HFB product and 
as a result, the expenses are then higher.  
 
5.2.5 Total manufacturing cost 
 
The total manufacturing cost of the STR process is 641 k€, or 2.7 k€/g and if the 
same downstream processing cost is applied to the HFB process, the total 
manufacturing cost is 631 k€, or 2.7 k€/g (Table 41). 
 
Table 41. The total manufacturing cost of the Mab production in HFB and in STR 
processes. 
 HFB STR 
manufacturing cost of USP 327 k€ 333 k€ 
DSP cost of the STR process (USP:DSP ratio 52:48)  308 k€ 
Total manufacturing cost 635 k€ 641 k€ 
Total manufacturing cost per gram 2.7 k€/g 2.7 k€/g 
 
However, as stated before, the savings in the filtration investment and operation 
costs due to much lower harvest volumes will lower the downstream processing 
manufacturing cost of the HFB option and result lower total manufacturing cost. 
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5.3 Conclusion 
 
Monoclonal antibodies can be produced in a variety of processes. The processes 
include different equipment types (e.g. stirred-tank bioreactor, hollow fiber 
bioreactor or disposable bag bioreactors) and several different product modes 
(batch, fed-batch and perfusion). These are discussed in more details in section 
2.3. In large scale, the stirred-tank bioreactor is usually the choice, also in 
monoclonal antibody production. In smaller scale, as in production of monoclonal 
antibodies for diagnostic of research use, also other equipment types are 
applicable. The perfusion process is the most efficient way to produce proteins, as 
higher cell concentrations can be achieved. In large scale, the fed-batch is still used 
more, as it is easier to operate and the contamination risk is smaller due to shorted 
culture period.  
 
In this study the perfusion stirred-tank bioreactor and hollow fiber bioreactor were 
compared techno-economically. In the scale of producing annually 234 g of purified 
Mab, the hollow fiber bioreactor and the stirred-tank bioreactor (equipped with a 
spin filter) are cost-wise comparable. Both bioreactors were run as perfusion 
processes, the HFB 60 days and the STR 30 days.  
 
The investment cost of the STR option is 1.7 times that of the HFB option, but the 
operating costs of the HFB option were higher and as a result, the upstream 
manufacturing costs are almost equal (HFB 327 k€, STR 333 k€). The result is in 
agreement with the general opinion, that in scale up to several grams, the HFB is 
viable and economical alternative (Griffiths, 2003; Jain and Kumar, 2008; Valdes et 
al., 2001; Yazaki et al., 2001).  
 
In the cost analysis, the direct operating costs (raw materials, consumables, utilities 
and labor expenses) covered 70 % of the upstream manufacturing costs in the HFB 
process and 55 % in the STR process. This is typical for a small scale process, 
where the investments are quite small.  
 
Labor costs alone accounted for 29 % of the upstream manufacturing costs in both 
processes. Investment depreciation covered 25 % of the upstream manufacturing 
cost in the HFB process and 40 % in the STR process.  
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The Mab purification costs were assumed to be the same for both processes, as 
same purification procedure was used and the purified amount of raw protein was 
the same. With this assumption, the downstream processing costs were calculated 
as 308 k€ and the total manufacturing costs were equal, 2.7 k€/g. However, the 
product concentrations and harvest volumes varied significantly, and this will likely 
reduce significantly the filtration expenses of the HFB process. The most expensive 
downstream processing unit is the affinity chromatography that is designed on 
product mass basis and the harvest volume variation will not have as large effect on 
these costs. The downstream manufacturing costs of HFB will probably be lower 
than estimated here.  
 
From technical perspective, the STR requires more cleaning and sterilization 
processes whereas the HF cartridges are operated as disposables. Both are 
operated automatically, but as the STR process runtime is only half that of the HFB 
process it needs more reactor turnovers. A disadvantage of the HFB process is 
larger contamination risk as the culture time is much longer. A possible 
disadvantage with the STR is the shear sensitivity of the hybridoma cells. Although 
many hybridomas are cultures in suspension, the specific production rate may be 
less than in HFB (Yang et al., 2004).   
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6 Crystallization of recombinant protein as a purification method 
 
 
Most recombinant proteins and especially monoclonal antibodies are purified using 
chromatographic methods. Affinity chromatography is used because of its high 
selectivity but the disadvantages include the low flow rate and high expenses 
(Kelley, 2007; Low et al., 2007; Sommerfeld and Strube, 2005). Especially as the 
titers have increased, the significance of the chromatographic purification cost in the 
manufacturing cost is revealed. Even 50 – 80 % of the total costs come from the 
downstream processing (Roque et al., 2004; Rouf et al., 2000; Sommerfeld and 
Strube, 2005) and typically the chromatography steps are the most expensive (Farid 
et al., 2005b).  
 
Alternatives for the expensive chromatographic purification have been searched, 
and among others, crystallization has been proposed e.g. by Kelley (2007), Low et 
al. (2007) and Schmidt et al. (2005). The advantages of the crystallization include 
high selectivity and low costs. The disadvantage is that no universal method is 
available, but the crystallization method must always be searched through elaborate 
experimental work.  
 
In this study we have developed a crystallization method for HIV-1 Nef protein that 
is typically purified by affinity chromatography. Nef proteins were crystallized for two 
different purposes: First, to create crystals big enough for x-ray structure studies 
and second, for studying the possibility to purify Nef (and possibly other GST-
tagged proteins) by means of crystallization.  
 
Many research groups have tried to crystallize the full-length Nef-protein, but have 
not succeeded (e.g. Franken et al., 1997; Lee et al., 1996). The Nef-protein core 
domain (HIV-1 NL4-3, residues 54-205) has been crystallized together with the Fyn 
tyrosine kinase SH3 domain (Lee et al., 1996) and again (HIV-1 LAI, residues 58-
206, Nef∆1,57) alone and with Fyn SH3 domain (Franken et al., 1997).  
 
As the full-length Nef has not been crystallized, also the structure has not been 
solved as whole. However, the structure has been constructed from the X-ray 
structure of the folded core domain and from the NMR-structures of the flexible 
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anchor domain. The Nef structure is presented in Figure 24 (Arold and Baur, 2001). 
The proteolytically cleaved core domain has been crystallized successfully 
unliganded (Franken et al., 1997) and in complex with the Fyn SH3 domain 
(Franken et al., 1997; Lee et al., 1996). 
 
 
Figure 24. The structure of Nef-protein (Arold and Baur, 2001). 
 
 
6.1 Nef crystallization screening conditions and results 
 
Nef-proteins were produced in E. coli and purified as described in Vermasvuori et 
al. (2009) 
 
Crystallization screens were performed in room temperature using the hanging-drop 
vapor-diffusion method in 24-well Lindbro plates (ICN, USA). The crystallization 
conditions were optimized by changing the protein and precipitant concentrations. 
Polyethylene glycol (PEG) 3350 (Sigma-Aldrich, Germany) and isopropanol 
(Rathburn, UK) were used as precipitants with Na-K phosphate buffer. The Na-K 
phosphate buffer was prepared by adding 4 M K2HPO4 to 4 M NaH2PO4 to desired 
pH at room temperature.  
 
The crystals grew from droplets containing 10 – 15 mg/ml protein, 10 mM Na-K 
Phosphate buffer (pH 6.9), 1 – 8% w/v PEG 3350 and 7 – 13 % v/v isopropanol 
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(IPA), against a reservoir solution containing 2 – 15 % w/v PEG 3350, 15 – 25 % v/v 
isopropanol and 20 mM Na-K-phosphate buffer (pH 7). Crystals were shaped as 
rods or needles (Figure 25), and were maximum 200 µm long. Only in few cases, 
the crystals were alone, and generally grew as star-like clusters (Figure 26).  
 
 
Figure 25. The rod-shaped Nef 
crystals (length ~ 200 µm). 
Crystallization conditions: protein 
concentration 15 mg/ml, PEG 3350 5 
%, IPA 20 %, Na-K-phosphate buffer 
(pH 7.0) 20 mM, RT 3 days. 
 
 
 
Figure 26. The star-like Nef crystal 
clusters (diameter ~ 50 µm). 
Crystallization conditions: protein 
concentration 10 mg/ml, PEG 3350 
10 %, IPA 20 %, Na-K-phosphate 
buffer (pH 6.9) 20 mM, RT 2 days. 
 
The crystallization conditions were screened further with different additives (Beta 
octyl-glucopyranoside (βOG), Dithioerythritol (DTE) and metal ions Ca, Mg, Li and 
Zn) but they did not improve the crystal quality. Micro-seeding was used in attempts 
to produce bigger crystals, but it did not help in producing bigger crystals. 
 
Small amount of crystals were gathered up from hanging-drop droplets and 
dissolved in NA-K phosphate buffer (pH 7). Then the solution was tested with SDS-
PAGE and the proteins were identified was Nef.   
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6.2 Batch crystallization 
 
Generally it is thought, that the batch crystallization by direct mixing of additives 
occurs at about 60 – 80 % of the concentration of the precipitant required in a 
hanging drop experiment (Chayen, 1998; Rayment, 2002). For example, if the 
hanging-drop conditions are (reservoir solution) 10 % w/v PEG, 20 % v/v IPA and 
20 mM Na-K-phosphate buffer (pH 6.9), the same proteins stock will probably 
crystallize when mixed 1:1 with a solution that contains 6 – 8 % w/v PEG, 12 – 16 % 
v/v IPA and 12 – 16 mM Na-K-phosphate buffer (pH 6.9).  
 
Batch crystallization was attempted with three different setups. First, the batch 
crystallization was performed in hanging-drop droplet against an empty reservoir, 
secondly in droplets against a reservoir containing 1:1 crystallization solution and 
water, and thirdly 1:1 of protein solution and crystallization solution in 1.5 ml 
eppendorf tube. In all setups, the protein stock was mixed 1:1 with crystallization 
solution.  
 
In first setup the crystallization solution was too strong (Na-K phosphate buffer 20 or 
50 mM, PEG 3350 10 – 50 % and IPA 20 – 50 %) and in most droplets amorphous 
precipitate was formed in 24 hours. In the only droplet to form plain crystals the 
protein stock was mixed 1:1 with a solution containing 50 mM Na-K phosphate 
buffer, 10 % PEG 3350 and 20 % IPA.  
 
In second setup, small crystals were formed in 48 hours in droplets were the 
crystallization solution used contained Na-K phosphate buffer 20 mM, PEG 8 – 20 
% and IPA 20 %. Bigger crystals (without amorphous precipitation) grew from a 
droplet where the protein stock was mixed 1:1 with a solution containing 50 mM Na-
K phosphate buffer, 10 % PEG 3350 and 20 % IPA.  
 
In third setup the same solution that produced crystals in second setup was mixed 
into a 1.5 ml eppendorf tube. Protein stock was mixed 1:1 with a solution containing 
50 mM Na-K phosphate buffer, 10 % PEG 3350 and 20 % IPA. No crystals or 
amorphous precipitation was seen within 2 weeks.  
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6.3 GST-Nef crystallization 
 
A GST fusion protein that contains the DNA binding domain (16 – 115) of DREF has 
been crystallized by Kuge et al. (1997). They also suggested, that as the structure 
of a GST-molecule is known, the structure of a GST-fusion protein would be easier 
to solve than the structure of the target protein alone. Zhan et al. (2001) says, that 
the GST-fusion proteins could be crystallized easier using a standard method that 
they call the GST-driven crystallization. They summarize the crystallization of three 
GST-fusion proteins, and found out, that in every case, 30 – 60 % PEG (molecular 
weight 3350 or 4000) was used as a precipitant. The peptides crystallized as fusion 
proteins were only 5 – 42 residues in length.  
 
Here, the crystallization of un-cleaved GST-Nef fusion protein was attempted with 
few different PEG and isopropanol conditions (PEG 3350 10 – 20%, IPA 10 – 20%, 
0 or 20 mM buff (pH 6.9), but no crystals were observed. Later in SDS-PAGE it was 
seen, that the protein stock had been fragmented.  
 
 
6.4 Conclusion 
 
The crystallization method for HIV-1 Nef protein was developed, but the protein 
crystallized only in small scale hanging-drop experiments and not in batch 
experiments (1.5 ml eppendorf tupe). Also the crystallization of the uncleaved GST-
Nef proteins did not succeed, probably because of the fragmented protein stock.  
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7 CONCLUSIONS 
 
 
Recombinant proteins and antibodies for pharmaceutical or diagnostic use can be 
produced in many different host organisms (microbial, insect and mammalian cells), 
in a variety of different bioreactors (e.g. stirred-tank bioreactor, hollow fiber 
bioreactor and disposable bag bioreactors) and using different feeding strategies 
(batch, fed-batch or perfusion). The manufacturing cost (€/g) of the product 
depends on the characteristics of the production host (growth rate, productivity) and 
on the production method (cell density of the bioreactor phase and the overall yield). 
Most critical variables are the fermentation titer and the overall yield.  
 
The fermentation titers have already increased significantly over last years and now 
the focus is on upstream and downstream processing methods. The economical 
comparison of different processing methods is straightforward, if only titer and/or 
yield are changed and the process is otherwise kept the same. But if two different 
hosts are compared for commercial production, the comparison is more difficult as 
the processes may be completely different. In this study, the production of 
recombinant HIV-1 Nef protein was produced in three different host systems (E. 
coli, P. pastoris and Drosophila S2) and the processes were analyzed techno-
economically. The bacterial host was found to be the lowest cost system with a 
manufacturing cost of 100 mg of Nef about 6 460 €. The manufacturing cost of the 
P. pastoris and Drosophila S2 systems were about two and almost four times 
higher. The low cost of the E. coli system is mostly due to the fast growth rate and 
high titer. Therefore, if no post-translational modifications are required, the 
bacterium is usually the choice.  
 
The equipment type and feeding strategy affect the titer and manufacturing costs 
significantly. In this study, the production of monoclonal antibody in perfusion 
stirred-tank bioreactor and in hollow fiber bioreactor was economically compared. In 
scale 234 g of Mab per year, the investment cost of the STR system was 451 k€ 
and of the HFB system 271 k€. The upstream manufacturing costs were almost 
equal, USP manufacturing cost of the STR was 333 k€ and of the HFB 327 k€. If 
the scale is increased, the stirred-tank bioreactor would probably be more 
economically viable, because of the higher direct operating costs of the HFB 
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system. The downstream processing manufacturing cost of the HFB is lower due to 
smaller volumes and higher concentrations and therefore the total manufacturing 
cost of the HFB is lower.  
 
Downstream processing costs are significant in biopharmaceutical production, even 
50 – 80 % of the total costs. Most expenses emerge from the expensive 
chromatography steps. Still, the typical purification process uses several 
chromatographic methods. Expanded and simulated moving beds, membrane 
chromatography, precipitation and crystallization have been presented as 
alternatives for affinity chromatography. The use of crystallization is limited because 
no universal crystallization method is available, but the method and crystallization 
conditions must be searched for each protein separately. In this study the 
crystallization method for HIV-1 Nef was developed. The crystallization occurred in 
hanging-drops in room temperature and pH 7 with PEG 3350 and isopropanol as 
precipitants. Obtained crystals shaped as needles or rods. 
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